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Abstract 
The toxicity of mercury is dependent on its chemical composition at its point of 
entry and site of toxicity. Differences in toxicity indicate that inorganic mercury (iHg) 
and methylmercury (MeHg) mediate adverse reactions via different mechanisms. Based 
on the available toxicity data, demethylation of MeHg to iHg has proven detrimental as it 
increases the severity of toxic insult. Accordingly, an in vitro system was established in 
order to characterize the demethylation reaction using primary astrocytes from neonatal 
rat cerebellum. Incubation of MeHg with a pro-oxidant increased the rate of 
demethylation (control vs. rotenone = -1.86±5.57% vs. 16.27±2.68%, p<0.05) and 
accumulation (control vs. rotenone = 86.53±4.14ng/mg vs. 123.6±3.80ng/mg, pO.OOl) 
relative to control. These findings suggest that demethylation is not only harmful as a 
result of increased iHg levels, but also because total mercury is increased. In light of 
rising atmospheric mercury levels, it is important that this pathway be fully characterized. 
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Glossary 
Anti-oxidant: A molecule capable of neutralizing a free radical. 
Asphyxiation: A condition in which the amount of oxygen decreases and carbon dioxide 
increases. This leads to a loss of consciousness and death in more severe cases. 
Neonatal animals contain special oxygen carriers which are more resistant to low 
oxygen levels. 
Astrocytes: Support cells in the brain. Astrocytes are responsible for maintaining the 
blood-brain-barrier and carry out metabolic and immunological support for the 
neurons. 
Blood-brain-barrier (BBB): A specialized pairing of endothelial cells (blood vessels 
cells) and astrocytes which provide a strong barrier to prevent contents present in 
blood from entering the brain. 
Cell: The basic unit of life. Cells are comprised of organelles which are essential for 
proper function. 
Central Nervous System (CNS): The part of the nervous system which encompasses the 
brain and spinal cord. 
Demethylation: The conversion from organic mercury to inorganic mercury 
Electron transport chain: A series of enzymes which function to produce energy as 
ATP (see mitochondrion) in the mitochondrion through movement of protons and 
electrons. 
Endogenous: Something present in an organism that was produced by that organism. 
Exogenous: Something present in an organism that was not produced by that organism. 
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FACS: Flow assisted cell sorting. An analytical device used to sort and quantify particles 
based on size, granularity, and presence of specific fluorescent markers. 
Free Radical: A highly reactive atom or molecule with a free electron. 
Glia: The "housekeeping" cells in the brain. Glial cells (astrocytes, microglia, and 
oligodendrocytes) are responsible for maintaining and optimizing the 
microenvironment of the nervous system. 
Glutathione (GSH): A molecule consisting the amino acids glycine, cysteine, and 
glutamate. GSH is involved in many metabolic reactions and also acts as an anti-
oxidant. 
In vitro: Latin for "in glass". In biological terms, this refers to growing biological cells 
and tissues in specialized dishes. 
In vivo: Latin for "in life". This refers to subjecting a whole animal to an experiment 
while still living. 
Minamata disease: Mercury toxicity resulting from chronic exposure to mercury 
contaminated fish from Minamata Bay, Japan. 
Mitochondrion: An organelle within the cell which is responsible for the cell's energy 
production in the form of adenosine triphosphate (ATP). The number of 
mitochondria within a cell is proportionate to the cell's energy requirements. 
Neurons: The cells of the nervous which transmit electrical impulses for the purpose of 
thought, emotion, and movement. 
Oxidative stress: An overwhelming excess of free radicals which surpass an organism's 
antioxidant capabilities. 
Postnatal: After-birth 
vii 
Pro-oxidant: A molecule which itself releases or increases production of free radicals. 
Anti-oxidants in high concentrations have the potential to become pro-oxidants. 
Reactive Oxygen Species (ROS): A free radical which contains oxygen. 
Superoxide anion: A highly reactive free radical which is formed when an extra electron 
binds to an oxygen molecule. 
Synchrotron: A high powered particle accelerator used for a variety of scientific 
applications spanning several disciplines. 
Toxicant: Any chemical, naturally-occurring or anthropogenic in origin, that causes an 
adverse effect to an organism 
Toxicokinetics: The study of the effects of a biological system on a chemical. This 
includes the absorption, distribution, metabolism, and elimination. 
Toxicodynamics: The study of the effects of a chemical on a biological system. For 
example, increased neurotransmitter levels in the brain following exposure to 
mercury. 
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1 Introduction 
1.1 Mechanisms of mercury toxicity 
The primary mechanism by which mercury, both inorganic (iHg) and organic 
(MeHg), exerts its toxic effects is through the binding of sulfhydryl groups on protein 
residues which may lead to altered protein function (2005b; Cabanero et al., 2005; Costa et 
al., 2004; Fitsanakis & Aschner, 2005; Gailer et al., 2000; Szasz et al., 2002). The 
manifestation of Hg toxicity is likely due to secondary effects including alterations of 
calcium homeostasis (Limke et al., 2004), and generation of reactive oxygen species (ROS) 
(Dreiem et al., 2005; Chapman & Chan, 1999; Allen et al., 2002); which ultimately lead to 
cell death and other toxic responses. 
1.1.1 Sulfhydryl Binding 
The binding of mercury to proteins containing sulphur groups has been noted in the 
literature in both iHg and MeHg (ATSDR, 1999). This mechanism results in a broad range 
of toxicities consequential of the modification of protein structure and function (Costa et al., 
2004) although there appears to be some degree of specificity (Limke et al., 2004) as noted 
by the distribution of MeHg in the adult brain (Eto, 2000). This may therefore translate to 
various pathologies: Allen et al. (2001) noted an inhibition of the enzyme glutamine 
synthetase, in part, by thiol binding. Moreover, Hg has been shown to inhibit sarcoplasmic 
ATPases resulting in alteration of calcium homeostasis (Abramson et al., 1983). 
1.1.2 Alterations to calcium homeostasis 
Hg-mediated toxicity, as described above, often leads to secondary effects which are 
the true basis for the observed toxicity. One such effect is the alteration of calcium 
homeostasis. The mechanisms in which this occurs are numerous. Basu et al. (2005b) noted 
inhibition of muscarinic ACh receptors following incubation with mercury in vitro which 
has been suggested to cause calcium release from intracellular stores (Limke et al., 2004). 
Moreover, Hg-induced damage to organelles which store calcium, such as the smooth 
endoplasmic reticulum and the mitochondrion, has been noted to lead to increased intra-
cellular calcium levels (Somlyo et al., 1985). The mechanism in which calcium results in its 
toxicity has been well characterised. An early study showed that removal of extracellular 
calcium increased survival of neurons in vitro (Choi, 1985). Elevated calcium levels can lead 
to cell death through either apoptosis or necrosis pathways. Calcium has been found to 
activate the protease calpain which, if overexpressed, can lead to cleavage of vital proteins 
resulting in cytoskeleton disruption and subsequent death (Wang, 2000). Additionally, 
activation of calcium-dependent caspases and endonucleases leads to apoptosis and may lead 
to necrosis in the latter. Finally, calcium-induced activation of phospholipase A2 has been 
found to disrupt membrane stability leading to necrosis (Boelsterli, 2003). 
1.1.3 Oxidative Stress 
Mitochondria have been implicated as targets of MeHg - likely due to their 
lipophilicity (Aramaki et al., 2004) - leading to the formation of reactive oxygen species 
(ROS) (Dreiem et al., 2005). The presence of ROS in Hg toxicity cases has been reinforced 
by studies showing that antioxidants, such as vitamin E and selenium, increases survival in 
murine in vivo models (Beyrouty & Chan, 2006). Using primary rat neuron cultures, Dringen 
et al. (1999) showed that the major deoxidizing pathway in neurons involves catalase 
suggesting a rationale for greater susceptibility to toxicity in neurons than glial cells. 
Furthermore, Ali et al. (1992) found increased ROS production in rat synaptosomes, using 
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the fluorescent dye 2',7'-dichlorofluorescein-diacetate, especially in the cerebellum. It has 
been suggested that ROS production from mercury arises from homolytic cleavage of the 
carbon-mercury bond resulting in an alkyl radical (Ganther, 1978). However, if this were the 
source of ROS, the production of free radicals would only be equivalent to the rate of 
demethylation. As discussed in section 2, demethylation is a very slow process. Accordingly, 
this is not a significant source of ROS if it is indeed correct. A mechanistic study 
investigating the source of ROS in the brain found that mercury inhibited the ubiquinol: 
cytochrome c oxidoreductase region (complex III) of the electron transport chain (Yee & 
Choi, 1996). 
Oxidative stress may induce cytotoxicity by damaging DNA, proteins, or lipids. 
Damage to DNA in the form of base or sugar oxidation may lead to strand breaks, 
crosslinkages between two molecules (DNA-DNA or DNA-protein), and errors in DNA 
replication - all leading to cell death or tumour formation (Boelsterli, 2003). Similarly, 
oxidative protein damage can result in protein-protein cross-linking, fragmentation, and 
alternate folding if side chains are affected (Josephy, 1996). Lipid oxidation is slightly 
different in that the interaction of a lipid with a ROS results in the creation of a reactive 
lipid. Directly, lipid oxidation can lead to membrane damage and indirectly to any number of 
other forms of oxidative damage (Boelsterli, 2003). 
1.1.4 Glutathione 
As an addendum to oxidative stress, it is prudent to make mention the role of 
glutathione (GSH). GSH is a three amino acid complex consisting of cysteine, glutamate, 
and glycine. It functions to metabolize compounds by binding through its sulphur group and 
acts as an antioxidant and biomarker by quenching radicals through the formation of a 
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dithiol linkage with another GSH molecule (Josephy, 1996). Dringen et al. (1999) noted 
that neurons are less capable of handling oxidative stress than astrocytes, suggesting that 
GSH deficiencies play a key role in Hg-mediated toxicity in neurons. 
As mentioned above, Hg has the potential to cause toxicity mediated through the 
production of ROS. Astrocytes have been shown to be more resistant to cytotoxicity than 
neurons using in vitro models (Allen et al., 2002; Dringen et al., 1999; Morken et al., 2005). 
It should be noted, however, that a study conducted in monkeys showed a decrease in 
astrocytes and no change in numbers of neurons in chronic MeHg exposure studies 
(Charleston et al., 1996). This is in contrast to human cases in which chronic exposure 
showed loss of neurons in adults - particularly granule cells within the cerebellum and 
neuronal swelling in the cerebral cortex (Eto, 2000). Acute studies found loss of neurons and 
reactive proliferation of astrocytes (Eto et al., 1999). A rationale for the results seen through 
the in vitro models deals with the role of cysteine transport from astrocytes to neurons 
through a Na+ dependent cysteine transporter - a transporter which is absent in neurons and 
is controlled by glutamate and aspartate (Allen et al., 2002). Morken et al. (2005) showed 
that treating neuroglia co-cultures with 5uM MeHg increased neuronal GSH levels which 
improved survival rates suggesting a protective role of astrocytes on neuronal endurance. 
1.1.5 Glutamate Excitotoxicity 
Glutamate, the most common excitatory neurotransmitter in the brain, has been 
shown to exhibit toxicity when in excess in the extracellular matrix of the brain (Fitsanakis 
& Aschner, 2005). As previously mentioned, the cerebellum is a major target of Hg toxicity 
(Costa et al., 2004). This may be related to glutamate toxicity as the cerebellum is one of the 
most abundant areas of glutaminergic receptors in the brain (Matyja & Albrecht, 1993). 
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Following exposure to Hg, analyses have shown that there is a decrease in glutamate 
levels in neurons and an increase in astrocytes (Morken et al., 2005). This may be explained 
by the findings by Allen et al. (2001) that glutamine synthetase - the enzyme responsible for 
the conversion of glutamate to glutamine in astrocytes - is inhibited by HgC^ in vitro. 
Further studies have shown impairment of the excitatory amino acid transporters (EAAT) 
resulting in a build-up of glutamate in astrocytes and the extracellular matrix and a decrease 
inside neurons (Fitsanakis & Aschner, 2005). Excess glutamate in the extracellular space is 
thought to overstimulate the NMDA receptor (Allen et al., 2001; Allen et al., 2002; 
Fitsanakis & Aschner, 2005; Mariussen & Fonnum, 2001; Matyja & Albrecht, 1993) 
resulting in alterations to calcium homeostasis (Choi, 1985). Influxes of calcium result in a 
change in membrane potential and initiation of apoptosis (Limke et al., 2004). 
Boveris and Chance (1973) noted that the addition of glutamate increased ROS levels 
in mitochondria from pigeon hearts. A surplus of glutamate can cause impairments of Na+-
dependent cysteine transporters (Allen et al., 2002) leading to deficiencies in glutathione in 
neurons. This is likely why Dringen et al. (1999) found that neurons are less capable of 
detoxifying ROS by the GSH pathway than astrocytes. 
1.1.6 Selenium 
The role of selenium has been extensively studied as a possible treatment for Hg 
toxicity because, when co-administered, it appears to reduce the toxicity of iHg (Gailer et al., 
2000) and, when administered in combination with vitamin E, decreases MeHg toxicity 
(Beyrouty & Chan, 2006). Kasuya (1976) noted a four-fold increase in effectiveness in 
selenite when compared to the selenate species stating that a dose of 2xlO"6M sodium 
selenite was sufficient to protect against 10"5M MeHg when co-administered with primary 
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cerebellar neurons. In vivo studies have made similar findings. In Hybro-G female broiler 
chickens, addition of 0.2 mg/kg feed of both iHg and selenium reduced total Hg 
concentrations by as much as 60-100% while chickens exposed to MeHg prior to selenium 
administration did not show significant antagonistic effects from selenium (Cabanero et al., 
2005). In pike (Esox lucius), dietary intake of selenium reduced the amount of mercury 
absorbed from contaminated perch consumption by 5-11 % but had no effect on MeHg 
absorption from water (Cuvin-Aralar & Furness, 1991) suggesting that the protective effect 
of selenium occurs prior to absorption. Separately, Se and Hg contribute to oxidative stress 
in mallard ducks; however, when co-administered, they decrease toxicity (Hoffman & 
Heinz, 1998). It has been reported that the addition of selenium before Hg results in the 
methylation of selenium to dimethylselenide which is said to be toxic (Gailer et al., 2000). 
Interestingly, Yamane et al. (1977) found that 14C-labelled MeHg acted as a methyl donor to 
dimethylselenium, which was immediately exhaled (and is therefore non-toxic), resulting in 
the formation of iHg. 
1.2. Rationale for experiment 
MeHg and iHg have been compared in a number of studies (Monnet-Tschudi et al., 
1996; Basu et al., 2005b; Chapman & Chan, 1999). It has been found that although MeHg 
can readily cross the blood-brain barrier, iHg is more toxic and persistent once inside the 
brain (Dringen et al., 1999; Yasutake et al., 1998). Oxidative stress plays a key role in the 
demethylation pathway. The ability of antioxidants such as selenium and vitamin E to 
moderate toxicity through moderating demethylation is of key interest in decreasing the 
potential for toxicity. 
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1.3. General thesis objective 
There is overwhelming support for the theory of demethylation of MeHg in 
mammalian systems (Allen et al., 2001; Charleston et al., 1996; Hansen & Danscher, 1995; 
Monnet-Tschudi et al., 1996; Vahter et al., 1994; Vahter et al., 1995; Watanabe, 2002; 
Yasutake & Hirayama, 2001). The different rates of elimination of the two mercury species 
(Dringen et al., 1999; Yasutake et al., 1998) suggest that demethylation is a detrimental 
consequence. Although there have been mechanisms proposed to explain this reaction in the 
liver (Suda & Hirayama, 1992; Yasutake & Hirayama, 2001), no functional studies on this 
reaction have been evaluated in the brain to date. 
This thesis will examine the mechanism of demethylation of MeHg to iHg in vitro 
using primary astrocytes from rat cerebellum. First, an attempt will be made to establish a 
culture system in which doses low enough to be sublethal but sufficient for detection are 
utilized. Secondly, I will determine the effect of ROS on mercury concentration. Finally, I 
will attempt to identify the role of ROS in MeHg demethylation. The findings of this 
research may aid in decreasing mercury toxicity in exposed individuals. 
1.4. General thesis hypothesis 
Oxidative stress is responsible for driving the demethylation of MeHg into iHg. I 
believe that it can be altered such that the relative toxicity will decrease as elimination 
increases. 
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2 Publication I: Demethylation of methylmercury in the brain and its effects on 
neurotoxicity 
Aaron M. Shapiro and Hing Man Chan* 
Community Health Program, University of Northern British Columbia, Prince George, 
British Columbia, Canada 
"Corresponding author. Tel.: +1(250) 960-5237; fax: +1(250) 960-5892 
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Abstract 
Mercury is a naturally occurring environmental contaminant and a known 
neurotoxicant. A dynamic equilibrium exists between the elemental, inorganic, and organic 
forms, which affects the toxicokinetics. Methylmercury (MeHg) has been shown to 
accumulate in tissues, making it more toxicologically relevant than the non-cumulative 
inorganic form. However, in vitro data has shown that inorganic mercury (iHg) has greater 
potential for neurotoxicity through astrocyte dysfunction. This paper reviews the 
accumulation and relative toxicities of MeHg and iHg as they relate to the process of 
demethylation. Accumulation studies indicate that MeHg can access the brain but reaches a 
threshold. iHg continues to rise despite lowering mercury exposure over time. In neuronal 
primary cells and cell lines, MeHg is more potent a toxicant than iHg (MeHg vs. iHg 
1.93±0.27 vs. 39.88±23.32, n=3). However, glia and the brain as a whole are more sensitive 
to iHg than MeHg. In vivo results were difficult to compare due to the number of possible 
endpoints and a lack of reported internal doses. Demethylation has been shown in vitro 
under physiological conditions within 3 weeks and in vivo within a matter of months. Given 
that MeHg is more bioavailable from oral ingestion but iHg elicits greater toxicity in the 
brain, demethylation may exacerbate mercury-induced toxicity. It is therefore prudent that 
we further investigate the mechanism of demethylation in the brain to decrease mercury 
neurotoxicity. 
Keywords: Demethylation, Methylmercury, Inorganic Mercury, Brain 
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Introduction 
Mercury is an omnipresent environmental contaminant. Its accumulation in the 
environment is the consequence of both natural and anthropogenic factors: the former results 
from erosion of mercury-containing earth by wind and water and from volcanic activity. The 
latter is, in essence, an acceleration of the natural process through industrial practices such as 
mining, smelting, and incineration (ATSDR 1999). Three types of mercury are present in the 
environment. Elemental mercury (Hg ), a silver liquid commonly found in thermometers, 
certain fungicides, and electrical switches, has been noted to volatilize causing a significant 
exposure from inhalation in occupational settings (Tang & Li, 2006). Inorganic mercury 
(iHg), which includes the Hg+ and Hg2+ ions, is water soluble and is often bound to 
negatively charged elements forming mercury salts (U.S.EPA., 1997a). Organic mercury 
compounds, of which methylmercury (MeHg) is the most abundant, are highly lipophilic 
substances created by methylation of iHg through both abiotic and biotic pathways. Abiotic 
factors include UV radiation from the sun (Siciliano et al., 2005) and the complexing of 
methylated compounds to iHg in aquatic ecosystems (Celo et al., 2006). Biotic methylation 
occurs mainly in anoxic conditions where sulphates are limiting by sulphate reducing 
bacteria in aquatic sediments (Compeau & Bartha, 1985). 
Absorption of MeHg and iHg by oral exposure is 85-100% and 7-15%, respectively, 
making MeHg the more toxicologically relevant form of mercury (National Research 
Council, 2000). The primary route of exposure to MeHg in humans is through the 
consumption offish and marine mammals. 
Hg speciation - the conversion between species of mercury - is an important factor 
for determining the internal dose in the target organ (i.e. the CNS). Toxicokinetics including 
absorption, distribution, and elimination are all governed by the species of mercury. 
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Yasutake and Hachiya (2006) found accumulation of iHg in rat hair following exposure to 
20ug HgCk/mL drinking water which was about 1/6 that of MeHg accumulation. 
Intraperitoneal exposure of MeHg in pregnant Sprague-Dawley rats showed liver and kidney 
concentrations of total mercury to be approximately double that of the brain in 1 and 7 day 
postpartum progeny (Smith et al., 1983). Human autopsy cases from Japan following MeHg 
exposure have reported accumulation rates in hundreds of ng/g for the liver and kidneys and 
only a tenth of the concentration in the cerebellum and cerebrum (Matsuo et al., 1989). 
Differences in the kinetics of accumulation also exist between iHg and MeHg. A 
study in rats looking at mercury vapour as a source of iHg determined a biological half-life 
of over 30 weeks following 12 hour exposure to 25 ug/m3 of mercury vapour in air 
(Pamphlett & Coote, 1998). Another study in rats revealed a biological half-life of 
approximately 7 days following a single intravenous injection of 0.5mg/kg MeHg (Sundberg 
et al., 1998). MeHg feeding trials in monkeys investigated the toxicokinetics in the thalamus. 
Levels of MeHg reached a plateau at about 12 months of dosing while iHg continued to rise 
(Charleston et al., 1996) suggesting a half-life of MeHg in the order of months and an 
indeterminate clearance rate for iHg. Voluntary ingestion of 203Hg-methylmercury revealed a 
whole body half-life of 70-80 days while blood half-lives ranged from 48-53 days (Miettinen 
et al., 1971), which is consistent with previous findings (Aberg et al., 1969). In contrast, 
biological half-lives for iHg are 60 days in whole body which is consequent of retention in 
the kidneys following either inhalation of mercury vapour and oral consumption of iHg 
(Agency for Toxic Substances and Disease Registry, 1999). Using oral doses of iHg in 
human volunteers, Rahola et al. (1973) found a half-life of 20 days in the brain. 
The above data suggests that MeHg has greater potential to accumulate in the body 
than iHg with the exception of in the kidneys. However, demethylation has been seen 
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observed over time in both animal models (Charleston et al., 1996; Pamphlett & Coote, 
1998; Vahter et al., 1995) and human populations (Eto, 2000; Amin-Zaki et al., 1974). The 
determining factors for the process of demethylation, particularly in the CNS, are not fully 
understood. 
The purpose of this paper is to review the difference between the toxicities of iHg 
and MeHg in the CNS. We also want to investigate the potential factors affecting 
demethylation - the conversion from MeHg to iHg - in different brain regions. 
Accumulation in the CNS from Oral Exposure 
Chronic exposure data from Minamata, Japan has shown that MeHg has the ability to 
accumulate in the brain (Takeuchi & Eto, 1999). Although exposure data from human 
volunteers exists, the number of volunteers per study and doses do not provide adequate data 
for accumulation studies. Accordingly, this section will address quantitative data collected in 
rats and monkeys following oral ingestion of MeHg as summarized in Table 1. The values 
expressed in the column "% of total ingested" were calculated according to the formula 
presented in Figure 1. 
, , Brain Hg(ug I g)x brain massig) ,™n, 
Percent accumulated = 6VM5 6J — 100% 
Oral Dose(mg I kg) x Body Mass(kg) x 1000//g/mg 
Figure 1: Calculation of percent mercury accumulation in the brain following oral exposure. Values are given 
in Table 1. Reported brain and body masses were used where applicable. Reported averages were used when 
brain and body masses were not given. 
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Table 1: Accumulation in the CNS from oral consumption 
Rat 
Tissue 
type 
Whole 
brain PD1 
Whole 
brain PD1 
Whole 
brain 
PD14 
Whole 
brain 
PD14 
Whole 
brain 
PD35 
Whole 
brain 
PD35 
Cerebellu 
m Adult 
Male 
Whole 
Brain 
Adult 
Male 
Whole 
Brain 
Adult 
Female 
Whole 
Brain 
Adult 
Female 
Whole 
Brain 
Adult 
Female 
Whole 
Brain 
Adult 
Female 
Whole 
Brain 
Adult 
Female 
Whole 
Brain 
Adult 
Female 
Ingested 
quantity 
ofMeHg 
1 
mg/kg/day 
10 
mg/kg/day 
1 
mg/kg/day 
10 
mg/kg/day 
1 
mg/kg/day 
10 
mg/kg/day 
5mg/kg/da 
y 
10mg/kg 
0.84mg/kg 
5 
times/wee 
k 
0.84mg/kg 
5 
times/wee 
k 
0.84mg/kg 
5 
times/wee 
k 
3.36mg/kg 
5 
times/wee 
k 
3.36mg/kg 
5 
times/wee 
k 
3.36mg/kg 
5 
times/wee 
k 
Number 
of doses 
10 
10 
10 
10 
10 
10 
12 
1 
4 
9 
14 
4 
9 
14 
External 
Dose 
(mg/kg) 
10 
100 
10 
100 
10 
100 
60 
10 
3.36 
7.56 
11.76 
13.44 
30.24 
47.04 
Internal 
Dose 
(ug/g) 
1.58 
20.3 
2.34 
30.4 
1.42 
24.3 
14.0 
3.78 
1.00 
2.20 
2.90 
4.20 
9.80 
16.3 
Clearance 
Time 
(days) 
0 
0 
0 
0 
0 
0 
13 
5 
0 
0 
0 
0 
0 
0 
% of total 
ingested 
accumulated in 
the brain 
0.84 
1.08 
0.56 
0.73 
0.15 
0.26 
0.01 
0.19 
0.22 
0.22 
0.19 
0.24 
0.24 
0.26 
Reference 
(Sakamoto & 
Nakano, 
1995) 
(Sakamoto et 
al., 1993) 
(Sakamoto & 
Nakano, 
1995) 
(Sakamoto et 
al., 1993) 
(Sakamoto & 
Nakano, 
1995) 
(Sakamoto et 
al., 1993) 
(Yamashita et 
al., 1997) 
(Clausing et 
al., 1984) 
(Magos & 
Butler, 1976) 
(Magos & 
Butler, 1976) 
(Magos & 
Butler, 1976) 
(Magos & 
Butler, 1976) 
(Magos & 
Butler, 1976) 
(Magos & 
Butler, 1976) 
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Cerebrum 
PD1 
Cerebellu 
mPDl 
Whole 
Brain 
Male 
Whole 
Brain 
Male 
Whole 
Brain 
Male 
Whole 
Brain 
Male 
Whole 
Brain 
Male 
5mg/kg/da 
y 
5mg/kg/da 
y 
lmg/kg/da 
y 
5mg/kg/da 
y 
5mg/kg/da 
y 
5mg/kg/da 
y 
5mg/kg/da 
y 
30 
30 
1 
1 
4 
8 
12 
150 
150 
1 
5 
20 
40 
60 
18.9 
18.5 
0.22 
1.25 
5.30 
12.5 
23.6 
0 
0 
7 
7 
7 
7 
7 
0.21 
0.07 
0.11 
0.13 
0.13 
0.16 
0.20 
(Sakamoto et 
al., 1998) 
(Sakamoto et 
al., 1998) 
(Suda et al., 
1989) 
(Suda et al., 
1989) 
(Suda et al., 
1989) 
(Suda et al., 
1989) 
(Sudaetal., 
1989) 
Monkey 
Tissue type 
Whole Brain 
Infant 
Thalamus 
Female 
Occipital 
Lobe female 
Thalamus 
Female 
Occipital 
Lobe female 
Thalamus 
Female 
Occipital 
Lobe female 
Thalamus 
Female 
Occipital 
Lobe female 
Thalamus 
Female 
Thalamus 
Female 
Thalamus 
Female 
Thalamus 
Female 
Ingested 
quantity 
ofMeHg 
0.02mg/kg 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
0.05mg/kg 
/day 
Number 
of doses 
4 
180 
180 
360 
360 
480 
480 
360 
360 
180 
360 
480 
360 
External 
Dose 
(mg/kg) 
0.08 
9 
9 
18 
18 
24 
24 
18 
18 
9 
18 
24 
18 
Internal 
Dose 
(ug/g) 
0.1 
1.7 
0.6 
1.8 
0.3 
1.6 
0.3 
0.1 
0.0 
3.517 
5.133 
5.162 
0.775 
Cle 
ara 
nee 
Ti 
me 
(da 
ys) 
0 
0 
0 
0 
0 
0 
0 
180 
180 
0 
0 
0 
180 
% of total 
ingested 
accumulated in 
the brain 
12.798 
0.037 
0.006 
0.018 
0.001 
0.012 
0.001 
0.001 
0.000 
0.077 
0.057 
0.043 
0.009 
Reference 
(Burbacher et 
al., 2005) 
(Vahter et al., 
1994) 
(Vahter et al., 
1994) 
(Vahter et al., 
1994) 
(Vahter et al., 
1994) 
(Vahter et al., 
1994) 
(Vahter et al., 
1994) 
(Vahter et al., 
1994) 
(Vahter et al., 
1994) 
(Charleston et 
al., 1996) 
(Charleston et 
al., 1996) 
(Charleston et 
al., 1996) 
(Charleston et 
al., 1996) 
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Using the chemical abstracts database for MeHg from SciFinder Scholar and the 
keywords accumulation and brain, we found 21 examples of MeHg dosing ranging from 
0.84mg/kg/day to 5mg/kg/day, in rats, for a period ranging from 1 to 30 days. External doses 
ranged from.l to 150 mg/kg and internal doses ranged from 0.22 to 30.4 u.g/g. Percent of 
accumulation from oral ingestion ranged from 0.01 to 1.08%. Discrepancies between 
external and internal doses are resultant of different tissues and reported brain regions. 
Monkey studies are rare, although thorough. Two studies were found in which 
female monkeys were exposed chronically (3 to 18 months). Additionally, one sub-chronic 
study examined whole brain in infants. The infant study reported a substantially higher 
percent ingested relative to brain and body mass when compared to the adult study (12.798% 
vs. 0.0218±7.4xl0" %). Dosing for the adult monkeys was 0.05mg/kg/day while the infant 
monkeys in the Burbacher et al. (2005) study received 0.02mg/kg/day. Accumulation in the 
adult studies ranged from 0 to 0.077% of the ingested quantity relative to brain and body 
mass. Interestingly, the internal doses reported by Charleston et al. (1996) were about 2-3 
fold higher than those reported by Vahter et al. (1994). 
It is difficult to draw conclusions involving the monkey data given the relatively few 
studies. Moreover, rat data is very short term (1-30 days) when compared to that of monkeys 
(3-18 months). This is likely due to the cost and labour intensiveness of working with 
primates when compared to rodents. 
Charleston et al. (1996) was the only report that we found to show speciation of 
mercury in the brain and report both internal and external doses. Following 6 months of 
MeHg exposure, 11% of the total mercury in the brain was iHg. This increased in the 12 and 
18 month exposure groups to 12% and 33%, respectively. In a fourth treatment group, in 
which monkeys were exposed for 12 months (as previous) then a 6 month clearance period, 
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79% of the total mercury (0.775 ug/g wet weight) in the brain was iHg. In this experiment, 
iHg was slightly higher than the normal 12 month exposed group (0.608 vs. 0.616 ug/g wet 
weight) while MeHg was substantially lower in the clearance group (4.526 vs. 0.159 ug/g). 
This shows that the rate of demethylation exceeds the rate of elimination of iHg from the 
brain (Charleston et al., 1996). 
Experimental findings from rat and primate models have revealed that minute but 
significant amounts of mercury accumulate in the brain following oral exposure. Variability 
may be resultant of the use of average brain masses when actual masses were not reported. 
Chronic MeHg exposure has been shown to decrease brain weights and is related to age of 
exposure (Sakamoto & Nakano, 1995) and brain region of interest (Pan et al., 2005). 
Therefore, calculated accumulation rates may be slightly lower and more inconsistent than 
actual values. However, the general trends - such as females accumulating more than males 
- should remain consistent. Conflicting results make it impossible to differentiate between 
groups at the neonatal stage. What is clear, however, is that infants accumulate more 
mercury in their brains following oral exposure than adults. 
Relative Potencies of Organic and Inorganic Mercury on Neuronal Endpoints 
The literature surrounding the relative toxicities of organic and inorganic mercury is 
somewhat divided. Discrepancies in the data may be attributed to the specific endpoint 
tested. This section summarizes the literature comparing both organic and inorganic mercury 
on various endpoints. In vitro data are tabulated in Table 2. In vivo studies are summarized 
in Table 3. 
In Vitro 
The cases described in Table 2 show conflicting results with respect to which 
mercury species is the more potent toxicant. Interestingly, MeHg was the more potent 
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species as measured by LD50 in all cases where purified neuronal cultures and cell lines 
(MeHg vs. iHg 1.93±0.27 vs. 39.88±23.32, n=3).In contrast, whole brain studies and 
purified astrocyte cultures showed greater toxicity when treated with iHg with the exception 
of the 25 day old culture conducted by Monnet-Tschudi et al. (1996). This suggests that 
there may be a different mechanism for toxicity in neurons and glia. This is in agreement 
with in vitro tests which show different rates of accumulation and metabolism of neurons 
and astrocytes (Syversen et al., 2006; Aschner et al., 2007). 
In an immature differentiated brain cell culture assay, iHg was reported to induce far 
greater toxicity than MeHg in astrocytes as assessed by glutamine synthetase activity 
(Monnet-Tschudi et al., 1996) and is consistent with results involving the use of purified 
astrocyte cultures (Allen et al., 2001). However, in more differentiated cultures, MeHg 
induced slightly greater toxicity than iHg in astrocytes and oligodendrocytes and drastically 
greater toxicity in neurons (Monnet-Tschudi et al., 1996). It has been suggested that the 
discrepancy is related to a holistic response caused by neuron dysfunction (Monnet-Tschudi 
et al., 1996) likely resulting from the establishment of cell-cell interactions such as gap 
junctions. 
Table 2: Summary of the available toxicity data comparing MeHg and iHg toxicities in vitro 
Cell line 
Tissue type 
HEK293 
(human 
kidney cells) 
NSC-34 
(neuron 
spinal cord 
hybrid) 
N18TG-2 
(neuroblasto 
ma) 
MeHg 
Quantity 
13.0uM 
1.74uM 
1.59uM 
iHg 
Quantity 
0.63uM 
7.95uM 
85.3uM 
Endpoint 
IC50 Neuronal T-
type Ca2+ channel 
inhibition 
LD50 
LD50 
Remarks 
iHg is a more potent 
inhibitor of T-type 
Ca2+ channels than 
MeHg 
MeHg is a more 
potent inducer of cell 
death 
MeHg is a more 
potent inducer of cell 
death 
Reference 
(Tarabova et al., 
2006) 
(Chapman & Chan, 
1999) 
(Chapman & Chan, 
1999) 
Rat 
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Tissue type 
neonatal 
Cortical 
astrocytes 
Fetal 
telencephalo 
n(5-15 day 
old culture) 
Fetal 
telencephalo 
n (25-35 day 
old culture) 
Neurons 
from granule 
layer 
Cerebellum 
(from PD7) 
Cerebral 
cortex 
Dorsal root 
ganglia 
neurons 
MeHg 
Quantity 
10 uM 
1 uM 
1 uM 
2.47 uM 
IC50: 
Ml:3.4u 
M 
M2:149n 
M 
100 uM 
iHg 
Quantity 
5uM 
1 uM 
1 uM 
26.40 uM 
IC50: 
Ml:2.2u 
M 
M2:5uM 
1-10 uM 
Endpoint 
Glutamine 
Synthetase from 
Astrocytes 
Astrocyte, 
oligodendrocyte, 
and neuron specific 
enzymes 
Astrocyte, 
oligodendrocyte, 
and neuron specific 
enzymes 
LD50 
50% binding 
inhibition 
GABA-induced 
electrical current 
Remarks 
iHg significantly 
lowered glutamine 
synthetase activity by 
45%(p<.001),MeHg 
inhibition was not 
significant 
iHg toxicity was 
greater for astrocytes 
than MeHg (90% 
reduction of 
Glutamine Synthetase 
versus 40% in MeHg) 
MeHg toxicity was 
greater for all cell 
types than iHg. 
Neuron specific 
enzymes choline 
acetyltransferase and 
glutamic acid 
decarboxylase were 
the most drastically 
affected. 
MeHg was approx. 
10-fold more 
cytotoxic 
For M2 binding 
inhibition, iHg was 
30 times as potent as 
MeHg. Little 
difference in potency 
for Ml binding 
inhibition. 
MeHg: suppression 
of electrical current 
iHg: enhancement of 
electrical current 
Reference 
(Allen etal., 2001) 
(Monnet-Tschudi 
etal., 1996) 
(Monnet-Tschudi 
etal., 1996) 
(Gasso etal., 2001) 
(Castoldi et al., 
1996) 
(Arakawa et ai., 
1991) 
Other 
Otter, mink, 
mouse, 
human 
Adult 
Female 
Cortex 
Otter, mink, 
mouse, 
human 
Adult 
Female 
Cerebellum 
Otter, mink, 
mouse, 
human 
Cerebral 
3.32 uM 
1.97 uM 
2.58-17.9 
uM 
1.67 uM 
1.7 uM 
1.41-8.13 
uM 
IC50 for muscarinic 
receptor binding 
IC50 for muscarinic 
receptor binding 
Inhibition of 
muscarinic receptor 
binding 
inhibited by iHg with 
greater potency than 
MeHg 
inhibited by iHg with 
greater potency than 
MeHg 
Otter is most 
sensitive, Human is 
least sensitive. 
Cerebellum is the 
(Basu et al., 2005b) 
(Basu et al., 2005b) 
(Basu et al., 2005b) 
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cortex 
Otter, mink, 
mouse, 
human 
Cerebellum 
1.59-13 
uM 
1.16-9.05 
uM 
Inhibition of 
muscarinic receptor 
binding 
most sensitive brain 
region 
Otter is most 
sensitive, Human is 
least sensitive. 
Cerebellum is the 
most sensitive brain 
region 
(Basu et al., 2005b) 
The degree of toxicity is also related to the specific endpoint. For instance, iHg was 
30-fold more potent an inhibitor of M2 muscarinic receptor binding than MeHg hydroxide, 
although there were no significant differences between the mercury species on the Ml 
receptor (Castoldi et al., 1996). Similarly, the neurotransmitter GABA has been shown to be 
affected by mercury. GABA-induced electrical current was enhanced by concentrations up 
to lOuM of iHg and suppressed by lOOuM MeHg (Arakawa et al., 1991). These results 
further substantiate the theory that the mechanism of toxicity between the two species is 
different. 
19 
Table 3: Summary of the available toxicity data comparing MeHg and iHg toxicities in 
different brain regions of various species in vivo. Estimated internal doses are given in 
italics based on most conservative values in table 1. 
Species 
Rat Sprague-
Dawley adult 
female 
Rat Wistar PD2 
RatWistarPD2 
Rat Sprague-
Dawley adult 
male 
Rat Sprague-
Dawley adult 
male 
Rat Sprague-
Dawley adult 
female 
Rat Sprague-
Dawley adult 
female 
Rat Sprague-
Dawley adult 
female 
Rat Sprague-
Dawley adult 
female 
Mouse ICR 
Hippocampus 
MeHg 
Quantity 
0.5,2 
mg/kg/day 
for 16 
days, oral 
.. . 
. . . 
5 
mg/kg/day 
for 7 days 
gavage 
(LOEL) 
7.5 
mg/kg/day 
for 10 days 
gavage 
(maximum) 
0.5 
mg/kg/day 
for 2 
months, 0.1 
mg/kg/day 
for 3 
months 
40, 400, 
4000 uM 
constant 
perfusion 
for 4 hours 
40,400, 
4000 uM 
constant 
perfusion 
for 4 hours 
... 
2,4,10 
mg/kg i.p. 
iHg Quantity 
... 
4 mg/kg/day 
for 58 days 
4 mg/kg/day 
for 58 days 
... 
... 
... 
... 
40,400,4000 
uM constant 
perfusion for 
4 hours 
10,100, 1000 
uM constant 
perfusion for 
3 hours 
... 
Internal 
Dose (|xg 
Hg/g wet 
tissue 
weight) 
1.83, 7.30 
. . . 
... 
5.37 
8.05 
6.85-2 
months 
2.05-3 
months 
... 
— 
... 
... 
Remarks 
Both doses significantly 
increased receptor density 
in the cerebellum. Only 2 
mg/kg/day increased 
hippocampal receptor 
density. 
Noradrenalin elevated in 
olfactory bulb, visual 
cortex, brain stem 
Decreased 
acetylcholinesterase 
activity in hippocampus 
Significant decrease in 
MAO activity in cortex, 
striatum, hypothalamus, 
hippocampus, brain stem, 
cerebellum 
Significant decrease in 
MAO activity in cortex, 
striatum, hypothalamus, 
hippocampus, brain stem, 
cerebellum 
Significantly greater 
release of dopamine in the 
brain independent of 
exposure route 
Dopamine levels increased 
by 900-9000% of basal 
levels 
MeHg and iHg increased 
dopamine levels at 
different times. MeHg 
caused far greater 
dopamine release. 
Suggests different 
mechanisms 
Dopamine levels 
significantly increased in 
100,1000 uM groups 
Glutamine synthetase 
activity was significantly 
Reference 
(Coccini et 
al., 2000) 
(Lakshmana 
etal.,1993) 
(Lakshmana 
etal., 1993) 
(Chakrabarti 
etal., 1998) 
(Chakrabarti 
etal., 1998) 
(Faro et al., 
1997) 
(Faro et al., 
2000) 
(Faro et al., 
2007) 
(Vidal et al., 
2007) 
(Kwon & 
Park, 2003) 
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Rat Sprague-
Dawley adult 
male 
Male mice 
(lmg/kg), rats 
(5mg/kg) 
Swiss albino 
mouse postnatal 
Swiss albino 
mouse postnatal 
Rat Wistar 
RatWistarPDl 
Rat Wistar PD 14 
&PD35 
Rat Wistar Adult 
male 
Monkey Adult 
female 
Contralateral 
Occipital Lobe 
Monkey Adult 
female 
Contralateral 
Occipital Lobe 
— 
1, 5 mg/kg 
i.p. 
— 
... 
— 
5 
mg/kg/day 
for 30 days 
10 
mg/kg/day 
for 10 days 
5 
mg/kg/day 
for 12 days 
0.05 
mg/kg/day 
for 6 
months 
oral 
— 
0,1, 2.0 or 
4.0mg/kg/day 
for 7 days 
— 
0.5 
mg/kg/day 
i.p. in mother 
1.5 
mg/kg/day 
i.p. in mother 
5 mg/kg/day 
for 5 days sc 
in PDl-5,8-
12 or 17-21 
— 
— 
— 
— 
0.2 
mg/kg/day 
i.v. 
... 
... 
... 
... 
... 
Cerebrum: 
18.9 
Cerebellum: 
18.5 (21) 
PD14: 30.4 
(64.5) 
PD35: 24.3 
(20.5) 
14.0 (9.2) 
iHg: 0.388 
MeHg: 
3.129 
Total: 3.517 
iHg: 0.616 
MeHg: 
0.159 
Total: 0.775 
inhibited in 4,10 mg/kg 
groups 
SOD activity decreased in 
the cerebellum but not in 
cortex or brain stem. GPx 
activity decreased (dose 
dependent) in the 
cerebellum (only 
significant at 4mg/kg) 
Significant increase in 
ROS production in the 
cerebellum from 5mg/kg 
MeHg. No other regions 
affected 
Weaning rats experienced 
increased Glutathione 
Reductase activity, 
impairment in motor 
performance in the rotarod 
task and decreased 
locomotor activity 
Weaning rats experienced 
increased TBARS activity 
PD1-5 group is most 
susceptible to toxicity as 
measured by behavioural 
deficits. No observed 
toxicity in PD 17-21 group. 
Severe hindlimb paralysis, 
loss of equilibrium, severe 
neurodegeneration 
Weight gain was 
significantly lower when 
compared to control 
Short-term increase in 
glutamine, nitrates, and 
nitrites in cerebrospinal 
fluid, increase in nitric 
oxide synthase in 
cerebellum 
Majority of iHg was found 
in astrocytes. Astrocyte 
numbers declined in 6 
month dosing group. 
Microglia numbers 
increased significantly in 
the presence of low level 
iHg 
(Hussain et 
al., 1997) 
(Ali et al., 
1992) 
(Franco et 
al., 2007) 
(Franco et 
al., 2007) 
(Peixoto et 
al., 2007) 
(Sakamoto 
etal., 1998) 
(Sakamoto 
et al., 1993) 
(Yamashita 
etal., 1997) 
(Charleston 
etal., 1996) 
(Charleston 
et al., 1996) 
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There is increasing literature investigating the use of neurochemical endpoints as 
biomarkers for toxicity due to their limited invasiveness and time utilization (Manzo et al., 
2001). Basu et al. (2005a) studied the inhibitory effects of Hg on muscarinic acetylcholine 
(ACh) and dopamine (D2) receptors in wild river otter. A negative correlation was found 
between concentrations of mercury and ACh and D2 receptor levels in the cerebral cortex 
and cerebellum. Similar correlations existed between iHg and MeHg on receptor binding (-
0.466 and -0.452, respectively) in the cerebral cortex although iHg was more potent than 
MeHg (Basu et al., 2005a). Further studies by Basu et al. (2005b) have shown that iHg is a 
more potent inhibitor of muscarinic receptor binding than MeHg and that the cerebellum is 
the most sensitive to mercury induced inhibition. 
It has been shown that neurons are more susceptible to MeHg toxicity than iHg while 
glia, of which astrocytes are the most abundant, are more vulnerable to iHg. This 
discrepancy implores the question of which species of mercury is more toxic to the brain as a 
whole. When considering that astrocytes comprise approximately 50% of the brain by 
volume and that astrocytes take up much of the mercury that reaches the brain, it may be 
inferred that neurotoxicity is a consequence of astrocyte dysfunction (Aschner et al., 2007; 
Brookes, 1992; Allen et al., 2001; Dave et al., 1994). It is therefore reasonable to conclude 
that iHg should be the species of greatest concern to neurological health. 
In Vivo 
The library of neurotoxicity studies involving animals exposed to MeHg is extensive. 
The purpose of this section is to provide a number of key examples for the purpose of 
comparing data to the in vitro reports and further comparing iHg and MeHg toxicity. Internal 
doses were only reported from oral MeHg exposure based on the percent accumulation 
values obtained in Table 1. Internal doses, where reported, were compared to estimates to 
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assess accuracy. The mean estimate was 119±33% of reported internal doses. Values ranged 
from 65.71% to 212.17%. There is considerable variability between the estimates and 
reported values likely due to the number of extrinsic factors (such as diet, age, weight, and 
handling).Coccini et al. (2000) evaluated the effects of in vivo exposure of MeHg on 
muscarinic receptors in adult female rats. Interestingly, MeHg dosing was found to increase 
muscarinic receptor density in the hippocampus and cerebellum at 2 mg/kg/day with no 
change in ligand binding affinity immediately after sacrificing the animals (Coccini et al., 
2000). However, binding affinity increased in an experimental group which was given a two 
week recovery period following MeHg treatment (Coccini et al., 2000). This suggests that 
receptor affinity and density may change over time. This may account for the differences 
observed ex vivo in otter, mink, mouse, and human tissues by Basu et al. (2005b). 
Lakshmana et al. (1993) noted a decrease in acetylcholine release in the hippocampus and 
suggested that this may be a response to alterations to another physiological process. It is 
therefore possible that the entire cholinergic pathway may be in a constant stage of change 
as it corrects for mercury-induced dysfunction. 
In addition to ACh levels, noradrenalin levels have been shown to be elevated 
following mercury exposure (Lakshmana et al., 1993). This is likely a result of inhibition of 
the monoamine oxidase (MAO) enzyme. MAO inhibition has been reported in adult male 
rats at a minimum dose of 5 mg/kg/day for 7 days and maximum dose of 7 mg/kg/day for 10 
days (Chakrabarti et al., 1998). Accordingly, dopamine levels have been noted to be 
elevated, likely as a result of MAO activity (Faro et al., 1997; Faro et al., 2000). A more 
recent report by Faro et al. (2007) showed that MeHg and iHg had similar potencies as 
measured by dopamine levels but followed different mechanisms as seen by the onset, 
duration, and quantity of dopamine released. 
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From the data presented, it is evident that there is substantial variability in the 
literature for in vivo toxicity endpoints of mercury. One major issue is that few papers report 
internal doses associated with the brain region studied. Faro et al. (2007) noted that in their 
whole body perfusion, only about 17% of the mercury reached the brain. Of that, the authors 
estimated submicromolar concentration in the dopamine secreting cells. Accordingly, the 
reported doses cannot be compared to those of other reports. 
Although literature exists in which internal doses are reported, finding similar 
endpoints in the same species is not possible nor can an interspecies comparison be made. 
As such, general observations are limited. 
One interesting observation can be made, however, regarding the age of exposure. As 
observed by Peixoto et al. (2007), early stages of development (especially PD1-5 8-12) are 
most sensitive when iHg neurotoxicity exists. Maternal exposure to iHg in weaning rats 
showed neurotoxicity in neonates but not the mothers (Franco et al., 2007). This may be due 
to delayed closure of the blood brain barrier in the first week post parturition (Hirase et al., 
1997). Additionally, weaning infants have different intestinal flora than those eating solid 
foods (Mackie et al., 1999). Intestinal flora is a main determinant in MeHg absorption and 
accumulation as bacteria can cleave the methyl group thus forming iHg (Rowland et al., 
1980). Accordingly, a lack of intestinal flora can increase the likelihood of experiencing 
neurotoxicity. 
Rate of Demethylation 
It has been well established that MeHg can be converted to iHg in mammalian 
species (Charleston et al., 1996; Norseth & Clarkson, 1970; Watanabe, 2002; Yasutake & 
Hirayama, 2001). Evidence for this phenomenon resulted from the identification of iHg in 
the brain following exposure to MeHg in humans (Takeuchi & Eto, 1999). This has since 
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been evaluated in vitro in the liver (Suda & Hirayama, 1992; Yasutake & Hirayama, 2001) 
and brain (Syversen et al., 2006) of rats and in vivo through feeding trials in monkeys 
(Bjorkman et al, 1995; Charleston et al., 1996; Watanabe, 2002; Vahter et al., 1995). 
MeHg dosing experiments in rats have evaluated the rate of demethylation in vitro 
through modification of oxygen radical levels in the liver and kidneys with limited work on 
the brain. Within 60 minutes, Suda and Hirayama (1992) showed significant demethylation 
from lOuM Fe(III)EDTA in liver microsomes. Yasutake and Hirayama (2001) showed the 
same effect in Hg-containing liver slices treated ex vivo with rotenone - a complex I 
inhibitor in the electron transport chain. Syversen et al. (2006) showed greater accumulation 
in neurons than astrocytes (75 and 47ng/mg protein, respectively) and determined that 
astrocytes but not neurons actively undergo demethylation. However, a relationship between 
demethylation rates cannot be established here since astrocytes were incubated for 3 weeks 
while neurons were only in culture for 1 week. This is also in contrast to previous findings 
both in vitro and in vivo (Charleston et al., 1995; Aschner et al., 2007). 
In vivo studies evaluating rates of demethylation are limited. Magos and Butler 
(1976) treated rats with MeHg for up to 64 days (at 1 dose per day) in various organs but did 
not observe demethylation (constant at 3.2% iHg) in brains in the 64 day dosing period. 
Hirayama and Yasutake (1999) showed that significant demethylation occurs within 24 
hours in the liver in the presence of 75mg/kg paraquat. To the best of our knowledge, this is 
the only study which has attempted to modify demethylation in the brain. Analysis of 
different brain regions in monkeys showed significant accumulation of iHg in the thalamus 
and pituitary following MeHg exposure (Vahter et al., 1995). Interestingly, iHg 
concentrations were several fold higher in the brains of MeHg exposed animals than those 
exposed to HgCk (Vahter et al, 1995). Similar studies showed that in 6-12 months, iHg 
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accounted for 9% of total mercury in whole brain (Vahter et al., 1994). On the cellular level, 
microglia and astrocytes showed the highest levels of iHg following oral administration of 
MeHg after 6 months. Neurons did not show demethylation at that stage but eventually did 
after 18 months albeit in smaller quantities than in glia (Charleston et al., 1995). MeHg 
levels were comparable between a group dosed for 12 months with a 6 month clearance and 
a group analyzed immediately after a 6 month dosing period. Levels of MeHg reached a 
plateau after 12 months of dosing while iHg levels continued to rise (Charleston et al., 
1996). 
Davis et al. (1994) reported on a family in the United States who, for a period of 3 
months, consumed pork products contaminated with MeHg. Following autopsy, the average 
proportion of iHg present in the brain (as quantified by brain region) in a 30 year old female, 
aged 8 years at the time of exposure, ranged from 82-100% of total mercury (Davis et al., 
1994). However, this number does not necessarily quantify demethylation alone as 
elimination of MeHg from the brain would also increase this proportion. 
The literature examining the rate of demethylation is limited. This may, in part, be 
attributed to a very slow rate of demethylation and mercury's complex biotransformation in 
the body. Although not well studied, demethylation is a significant concern with respect to 
the neurotoxicity of mercury. The next section deals with specific toxic endpoints from both 
inorganic and methyl-mercurial species. 
Two mechanisms underlying the demethylation of MeHg have been proposed: 
cleavage of the methyl group by intestinal micro-organisms and by reactive oxygen species 
(ROS) (Suda & Hirayama, 1992). As previously mentioned, MeHg is freely absorbed while 
only a fraction (7-15%) of iHg passes biological membranes (National Research Council, 
2000). Therefore, demethylation in the intestines would not account for the presence of iHg 
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in the brain (Yasutake et al., 1998). Moreover, Charleston et al. (1996) noted higher levels of 
iHg following oral MeHg exposure than intravenous (i.v.) injection of HgCh. Accordingly, 
the most significant source of iHg in the brain is most likely from MeHg demethylation in 
the brain. Findings that the proportion of brain MeHg decreases over time (Davis et al., 
1994) support the theory that demethylation must occur at the site of iHg accumulation - at 
least in the case of the brain. Alternative theories for the presence of iHg in the brain 
involving binding to micronutrients have been proposed (Friberg & Mottet, 1989). The main 
support for this is the presence of iHg in the brain following inhalation of elemental mercury 
vapour (Bjorkman et al., 1995; Friberg & Mottet, 1989; Leong et al., 2001). However, 
accumulation in the brain may be the result of passive diffusion of Hg° across the blood 
brain barrier (Aschner & Aschner, 1990). It is evident that both demethylation of MeHg in 
the brain and passage of Hg° across the blood brain barrier exist. However, we will focus 
only on demethylation which occurs in the brain over time as it is the more toxicologically 
relevant mode of exposure with respect to community health and non-occupational exposure. 
Implications for toxicity 
The previous section illustrates the significance of the two species of Hg in the brain 
from a toxicological perspective. There is substantial evidence to support the theory that iHg 
is more toxic at the site of injury than MeHg in astrocytes - the most predominant cell in the 
brain. Furthermore, astrocyte dysfunction has been shown to mediate neuronal loss (Aschner 
et al., 2007). However, in order to reach significant levels of iHg in the brain, distribution of 
Hg in the form of MeHg must first occur. This illustrates the importance of understanding 
the role of demethylation in the brain. This section will address current knowledge of the 
mechanisms underlying demethylation. 
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As mentioned, Suda and Hirayama (1992) demonstrated significant demethylation of 
both methyl- and ethylmercury through the production of hydroxyl radicals by incubation 
with 10 uM Fe(III)EDTA, suggesting that ROS are involved in the demethylation of MeHg 
through cleavage of the C-Hg bond. This has been further supported in recent years 
(Yasutake & Hirayama, 2001). One inconsistency exists, however, between the two studies: 
the former claims that cleavage was driven by the hydroxyl radical since the presence of a 
hydroxyl radical promoter was found to accelerate demethylation. Additionally, the use of 
hydroxyl radical scavengers decreased demethylation in some instances (Suda & Hirayama, 
1992). The latter speculates that superoxide is the species of interest since enhancement of 
hydroxyl radical production through iron chelators had no effect on demethylation nor did 
the use of hydroxyl radical scavengers (Yasutake & Hirayama, 2001). 
In their report, Yasutake and Hirayama (2001) noted that the superoxide anion has an 
extremely low half life in aqueous solution but is more stable in organic solutions. This was 
extrapolated to looking at lipophilic regions of the cells as the sites of demethylation. 
Because of their extensive double membrane structures, mitochondria were evaluated to test 
superoxide-mediated demethylation. As expected, using isolated mitochondria increased 
demethylation when compared to whole cells (Aramaki et al., 2004); however, this may be 
due to disproportionate amounts of ROS production or types of membrane proteins, to name 
two associated issues. The electron transport chain, located on the inner membrane of the 
mitochondria, has been said to be a "leaky" system as electrons can readily escape and react 
with O2 to form superoxide (Adam-Vizi, 2005). It is therefore reasonable to assume that 
mitochondrial ROS formation contributes to MeHg demethylation. 
The current standard set by the Canadian Food Inspection Agency is 0.5ppm total 
mercury in fish (Health Canada, 2007). Based on the benefits of omega 3 fatty acids and 
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other important nutrients from vitamin D, it is recommended that adults consume at least 
two- 150g servings per week offish (Health Canada, 2007). This would lead to an overall 
exposure of 200 ug of total mercury per week. Based on these values and the accumulation 
values generated in Table 1, one week's exposure would lead to 0.15 ug and 0.23 \xg of 
mercury per gram of brain tissue for men and women, respectively. 
Estimates obtained from acute data do not appear to accurately assess chronic 
exposure as modelled by Mfasicularis. This is likely because diffusion of MeHg into the 
brain is limited by a concentration gradient. In a MeHg feeding trial, total mercury hit 
threshold at approximately 5.1 ug Hg/g wet weight in the brain following 12 months of 
exposure to 0.05mg/kg/day (Charleston et al., 1996). Interestingly, the 18 month dosing 
group had roughly the same total mercury content as the 12 month group. The problem, 
however, was that the 18 month group had double the iHg content as the 12 month group 
(Charleston et al., 1996). A clearance period of 6 months following 12 months exposure was 
used to compare mercury levels to the 12 month group that was sacrificed immediately 
following exposure. As expected, MeHg levels dropped (from 4.526 to 0.159 ug/g). 
However, iHg actually rose slightly from 0.608 to 0.616. Based on the toxicokinetics of iHg, 
the greater potency of iHg to MeHg in vitro, and experimental findings that demethylation is 
occurring in the brain, we recommend that the current recommendations for exposure limits 
be re-evaluated. 
Conclusions 
Mercury, a persistent pollutant, occurs naturally in the environment. Generally, the 
toxicity of mercury is modulated by the toxicokinetics of the mercurial species. 
MeHg is readily absorbed while iHg absorption is limited (National Research 
Council, 2000). Similarly, the biological half-life of MeHg is roughly 70-80 days while the 
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rate of elimination of iHg is substantially slower (Aberg et al., 1969; Agency for Toxic 
Substances and Disease Registry, 1999; Miettinen et al., 1971). MeHg is more toxic than 
iHg when ingested orally due to its high absorption (Berntssen et al., 2003). In tissues such 
as the brain, most studies have found iHg to be the more toxic species (Basu et al., 2005b; 
Castoldi et al., 1996). 
It has been shown that in vitro analyses can only be compared to in vivo findings 
when reported in terms of tissue levels rather than concentration of culture medium 
(Meacham et al., 2005). We may, however, infer that iHg and MeHg induce neurotoxicity 
via different mechanisms (Faro et al., 2007).Cell type has been shown to play a significant 
role in toxicity. For example, astrocytes and neurons show different toxicities to each 
mercurial species (see table 2) and display different toxicokinetic properties such as rates of 
absorption and metabolism (Aschner et al., 2007). 
A review of the in vivo literature is not sufficient for direct comparisons of 
neurotoxicity by the two species of mercury due to issues of inconsistent reporting of 
internal mercury concentrations and differences in experimental conditions. As such, we 
have estimated internal doses based on accumulation data. 
In lieu of cell differences and the existence of MeHg demethylation, we recommend 
that the toxicokinetics of both iHg and MeHg species be considered for chronic risk 
assessment and treatment. 
Demethylation has been shown to occur in brain tissue following MeHg exposure 
(Bjorkman et al., 1995; Charleston et al., 1996; Eto, 2000; Watanabe, 2002). When 
considering all the above factors, a condition which would result in the greatest toxicity 
would involve the ingestion of MeHg, distribution to the brain, followed by conversion to 
iHg. Such is the case with oral exposure of MeHg. It is therefore essential that the 
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mechanism of this reaction be studied in greater detail in the brain as a means of controlling 
demethylation in vivo. 
We are currently exploring the fate of MeHg in primary astrocyte cultures under 
different conditions of oxidative stress in mitochondria and cytoplasm. We hypothesize that 
reductions in oxygen radical levels will limit the rate of demethylation, thus limiting the 
amount of mercury which remains in the cells following exposure. Further understanding the 
trends in accumulation, the toxicity of mercurial species - both in vivo and in vitro - and the 
factors influencing demethylation will aid in developing novel approaches to limit mercury-
induced toxicity in the central nervous system. 
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3 Interim Comments 
The previous section exemplifies the importance of understanding the demethylation 
of MeHg in the brain. Two main conclusions can be drawn from the previous section. The 
first conclusion is that accumulation is severely limited and elimination occurs more rapidly 
with iHg compared to MeHg. The second is that the mechanism in which MeHg and iHg 
cause toxicity is different (see table 2). In the brain as a whole and in astrocytes, iHg is more 
potent a toxicant than MeHg. We may therefore deduce that demethylation in the brain is of 
detriment to humans. It is therefore prudent that we understand the mechanism in order to 
limit the toxicity of mercury. The following section attempts to understand the reaction and 
provides suggestions for reducing toxicity. 
32 
4 Publication II: Characterization of demethylation of methylmercury in cultured 
astrocytes 
Aaron M. Shapiro and Hing Man Chan* 
Community Health Science Program, University of Northern British Columbia, 3333 
University way, Prince George, British Columbia, Canada, V2N 4Z9 
*Corresponding author: 
Hing Man Chan, Professor and BC Leadership Chair 
Community Health Program, University of Northern British Columbia 
3333 University Way, Prince George, British Columbia, Canada, V2N 4Z9 
email: lchan@,unbcca 
telephone: (250) 960-5237 
fax:(250)960-5163 
Keywords: Demethylation; Brain; Methylmercury; Inorganic Mercury Toxicity; Astrocytes 
33 
Abstract 
Mercury is a naturally occurring environmental contaminant that has been shown 
both experimentally and clinically to be neurotoxic. Mercury toxicity in organisms depends 
on the species of mercury exposed to the organism from the external environment, as well as 
the mercurial species that reach the target organs after distribution and metabolism. A steady 
emergence of inorganic mercury in the brain following chronic and accidental exposure to 
methylmercury has suggested that methylmercury undergoes demethylation. A better 
understanding of the mechanism through which demethylation occurs may aid in decreasing 
toxicity from mercury exposure. For the first time, we have demonstrated in an in vitro 
primary cell culture model that methylmercury is converted to inorganic mercury and the 
rate of demethylation is increased by oxidative stress. Astrocytes from neonatal rat pups 
cultured in the presence of the pro-oxidant rotenone and treated with methylmercury showed 
increased conversion to inorganic mercury (control vs. rotenone = -1.86±5.57% vs. 
16.27±2.68%, p<0.05). The increase in demethylation was also accompanied by an increase 
in total mercury accumulation. These results indicate that not only is demethylation 
damaging because inorganic mercury had been shown to be a more reactive species 
intracellularly, but it is also harmful due to increased total mercury accumulation. Our 
results provide a useful model to study the determining factors for the rate of demethylation 
of mercury in astrocytes and to explore potential ways to protect an organism from mercury 
toxicity. With global mercury levels on the rise, the need to reduce the toxicity of 
environmental pollutants has become paramount for human health. 
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Introduction 
Mercury is a widespread persistent environmental contaminant. For the purposes of 
this study, we will subdivide mercury into three species: elemental, organic, and inorganic. 
Elemental mercury (Hg°) is a silver liquid substance that has applications in industrial 
practices and is a major component of dental amalgams (2001). Exposure to mercury in its 
elemental form occurs primarily from the inhalation of the vaporized liquid (Tang and Li, 
2006). Since Hg° is uncharged, it may pass freely across the blood brain barrier (Aschner 
and Aschner, 1990). Inorganic mercury (iHg) exists in the environment either free in 
solution or bound to inorganic complexes (NRC2000). Methylmercury (MeHg), a common 
form of organic mercury, exists as the result of a conversion from iHg by methyltransferases 
present in bacteria (Siciliano and Lean, 2002; Compeau and Bartha, 1985), by UV radiation 
(Siciliano et al., 2005), and by methylating compounds in the environment (Celo et al., 
2006). MeHg is the most toxicologically relevant form of mercury. It is able to accumulate 
and virtually pass freely across biological membranes because of its lipophilicity (Aschner 
and Aschner, 1990) and its perceived resemblance to methionine at the blood brain barrier 
(Hoffmeyer et al., 2006). 
It is well understood that the degree of toxicity induced by exposure to mercury 
depends on which species of mercury is present (Basu et al., 2005; Carrier et al., 2001). For 
example, when iHg is consumed orally, approximately 7-15% is absorbed in the body; 
whereas, >95% of MeHg is absorbed by the same means of exposure (NRC 2000). However, 
it may be overlooked that the species of mercury found in the target organ may differ from 
its initial form, which each exhibit different toxicological properties. Hg° may undergo 
oxidation to form iHg in the environment through any number of reactions, while in living 
organisms this occurs via the hydrogen peroxidase-catalase pathway (U.S.EPA., 1997). 
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Similarly, MeHg has been shown to undergo demethylation (MeHg -> iHg) through abiotic 
and biotic pathways. Abiotic factors generally involve UV radiation from the sun (Siciliano 
et al., 2005). This has been noted to cause photodegredation through the generation of a Hg 
radical, resulting in the heterolytic cleavage of the Hg-C bond (Gardfeldt et al., 2001). 
Certain bacteria - including those of the intestinal tract - have the ability to demethylate 
MeHg (Rowland et al., 1980). In addition to intestinal flora, mammals have the ability to 
cleave the C-Hg bond in organs such as the liver and brain (Friberg and Mottet, 1989; 
Hirayama and Yasutake, 1999; Suda and Hirayama, 1992; Syversen et al., 2006; Vahter et 
al., 1995; Yasutake and Hirayama, 2001). Ideally, in order to limit mercury toxicity, 
intestinal demethylation should be enhanced, thereby reducing absorption. Furthermore, 
demethylation within organs should be avoided, as the clearance rate for iHg from organs is 
slower than that of MeHg (Burbacher et al., 2005) and the cellular toxicity of iHg is greater 
than it is for MeHg in the brain (Allen et al., 2001; Basu et al., 2005). 
Examination of gross brain pathology in victims of accidental Hg exposure in 
Minamata, Japan has revealed that the distribution of lesions depends on age of the person at 
the time of exposure (Takeuchi and Eto, 1999). Generally, fetal exposure resulted in non-
specific lesions; however, in adults, lesions were specific to the cerebellum and the central 
gyrus and occipital lobe of the cerebral cortex (Takeuchi, 1968). These lesions were marked 
by neuronal loss and increases in microglia and astrocytes (Takeuchi and Eto, 1999). 
Astrocytes have been shown to take up mercury preferentially over neurons 
(Charleston et al., 1996; Garman et al., 1975). Neurotoxicity following mercury exposure 
has been suggested to be, in part, due to failure of astrocytes to provide a suitable 
microenvironment to the neurons with which they interact (Allen et al., 2002). iHg has been 
shown to cause toxicity on various chemical endpoints with greater potency in astrocytes 
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while MeHg appears to be more potent in neurons (Allen et al., 2001; Castoldi et al., 1996; 
Gasso et al., 2001; Monnet-Tschudi et al., 1996). Taken together, this indicates that the study 
of demethylation is of greater consequence in astrocytes than neurons. Coincidently, 
preliminary data indicates that astrocytes undergo demethylation at a greater rate than 
neurons (Syversen et al., 2006, data not published). 
Clinical and experimental findings have found that demethylation occurs in the liver 
as a result of the interaction of MeHg with the superoxide anion (Yasutake and Hirayama, 
2001). However, despite clinical and in vivo support for demethylation, the mechanism has 
yet to be elucidated in the brain. The purpose of this paper is to understand the mechanism in 
which demethylation occurs in astrocytes by developing an in vitro system for its analysis. 
The hypothesis is that increased oxidation will increase the rate of demethylation of MeHg 
in astrocytes. An understanding of this mechanism may result in the development of 
methods to reduce demethylation, and thus lower mercury accumulation and toxicity. 
Materials and Methods 
Chemicals 
MeHg was obtained from Alpha Aesar (Ward Hill, MA, USA). Rotenone, DNase I, 
L-buthionine sulfoximine (BSO), fetal bovine serum (FBS), Dimethyl sulfoxide (DMSO), 
Poly-L-Lysine, protease, L-cysteine, and NaOH were obtained from Sigma Aldrich Canada 
(Oakville, ON, Canada). The Bradford protein assay was obtained from Biorad Laboratories 
(Hercules, CA, USA). Cell culture regents including Trypsin, Penicillin/streptomycin, 
Dulbecco's Modified Eagle Medium (DMEM), and TrypLE™ express were obtained from 
Gibco/Invitrogen Inc. (Burlington, ON, Canada). Medical grade CO2 was purchased from 
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Praxair Inc. (Prince George, BC, Canada). HgCb standards, C11SO4, and HC1 were obtained 
from Fisher Scientific (Ottawa, ON, Canada). 
Animals 
Animal handling and experimental protocols were approved by the University of 
Northern British Columbia Animal Care and Use Committee. Seven week old adult Sprague 
Dawley rats (Rattus norvegicus) were obtained from the Charles River Laboratories 
(Montreal, Quebec, Canada) and housed in 18 X 33 X 30 inch cages for breeding, and 19 x 
10.5 x 8 inch cages for holding and weaning at 22°C under a 12 hour light/dark cycle in 
accordance with the guidelines of the Canadian Council on Animal Care. Mating was 
accomplished by introducing two adult females into the male's cage. Females were removed 
from the breeding cages when they were visibly pregnant and relocated to the holding and 
weaning cages. 
Isolation of rat neonatal cerebellar cells 
On post-natal day (PD) 8, rat pups were first placed unconscious by CO2 
asphyxiation then decapitated using Mayo ToughCut scissors (Fine Science Tools, 
Vancouver, Canada). Cerebella were extracted from whole brain under a model 2600 
dissecting microscope (Ken-a-vision, Kansas City, Mo, USA) and pooled together in IX 
phosphate buffered saline (Fisher Scientific), et al. Tissues were finely diced with scalpels to 
maximize the surface area to volume ratio for chemical digestion in 0.25% trypsin and 5 
kU/mL DNase 1 for 45 minutes at 37°C. The trypsin reaction was stopped using an aliquot of 
FBS to a final concentration of 1%. Tissues were then mechanically passed through a 100 
micron filter. Cells were separated from non-dissociated tissues by centrifugation at 500xg 
for 10 minutes. 
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Purification of astrocytes from whole brain cells 
Brain cells were resuspended in DMEM containing 10% FBS, 100 units/mL 
penicillin and 100|ig/mL streptomycin, and plated on poly-L-lysine coated flasks at a density 
of approximately 106cells/mL. Cells were allowed to incubate under high humidity at 37°C 
with 5% CO2 until confluent. Selection was accomplished based on the ability of the 
astrocytes to divide in a culture with non-dividing contaminating cells; namely 
oligodendrocytes, microglia, neurons, and endothelial cells. Astrocyte purity was obtained 
by passaging cells three times prior to use. This method, when prepared with prenatal human 
brains, yields 90-100% purity at the third passage (Jack et al., 2005). 
Determination of purity using FACS 
In order to determine the purity of astrocytes isolated from whole brain tissue, cells 
cultures were analyzed using a BD FACSCalibur™ multipurpose flow cytometer (BD 
Biosciences) at the Biomedical Research Centre at the University of British Columbia 
(Vancouver, BC). Three cultures were used in the analysis: The human neuroblastoma line 
SH-SY5Y (American Type Culture Collection, Manassas, VA, USA), rodent astrocytes. 
Identification of cell type (neuron vs. astrocyte) was accomplished by comparing forward 
and side scatter from the emitting laser. 
Quantification of protein content using the Bradford Protein Assay 
Protein quantification was necessary in order to standardize the concentration of 
mercury in the samples. This was accomplished using the Bradford reagent assay kit (Bio-
Rad Laboratories). Bovine serum albumen standards and cell samples were prepared in 
triplicate and were treated with 250 jxL of the Bradford reagent, containing Coomasie 
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Brilliant Blue G-250 (Bradford, 1976). Following a 15 minute incubation period, the 
samples were read spectrophotometrically at 595 nm using a Multiskan EX™ plate reader 
(Thermo Electron). Sample absorbance values were compared to a calibration curve using 
bovine serum albumen standards to yield values of protein expressed in mg/mL. 
Comparison of oxidative stress using DCFH 
The purpose of monitoring ROS levels in the cells was to validate the claim that 
experimental demethylation was the result of oxidative stress rather than a side reaction with 
the treatment groups. ROS was quantified using the non-fluorescent dye 2,7-
Dichlorofluorescin diacetate (DCFH) which, when reduced by ROS to 2,7-
Dichlorofluorescein diacetate (DCF), yields a fluorescent emission at 525nm. Cell samples 
were dosed for 24 hours in the presence of a pro-oxidant. Rotenone, a complex 1 inhibitor in 
the electron transport chain, prevents the oxidation of nicotine adenine dinucleotide (NADH) 
leading to the production of the highly reactive superoxide anion in the mitochondria 
(Jacobson et al., 2005; Zeevalk et al, 2005). BSO, an inhibitor of glutamylcysteine 
synthetase - an enzyme essential for glutathione production (Griffith, 1982) - causes 
oxidative stress in vitro (Chen et al., 2005) by limiting the cell's antioxidant capabilities. 
After incubating cells with pro-oxidants, the cultures were washed in PBS and 
incubated in PBS containing 5uM DCFH for 15 minutes. The DCFH solution was then 
aspirated off and replaced with clean PBS. Cells were lysed using a Model 100 Sonic 
Dismemberer (Fisher Scientific) and collected in microcentrifuge tubes. The tubes were then 
centrifuged for 10 minutes at 25000 x g, and the supernatants were collected and transferred 
in triplicate to a 96 well plate. Fluorescence was measured using a Varioskan Flash® spectral 
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scanning multimode reader (Thermo Electron Corporation, Waltham Ma, USA) with an 
excitation wavelength of 504nm and emission wavelength of 525nm. Since a calibration 
curve cannot be generated for ROS detection, all values are reported as percent of control. 
Mercury Dosing 
Rodent astrocytes prepared as described above were grown to approximately 80% 
confluency in 12 well culture plates (Corning) as visually determined using an inverted 
microscope (Fisher Scientific). Prior to dosing, the cells were washed once with PBS before 
the addition of pre-mixed solutions of DMEM in the presence or absence of treatment 
reagents for 24 hours. At the end of the dosing period, cell treatments were aspirated and 
replaced with PBS for 15 minutes to account for mercury adsorption on the side of the flask 
(see Figure 2). PBS was then removed and 200uL of a commercially available lysis buffer 
(R&D Systems, Minneapolis, USA) was added and incubated at 4°C for approximately 15 
minutes. Samples were stored at 4°C in 500uL centrifuge tubes until ready for mercury and 
protein analyses. 
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Time (Minutes) 
Figure 2: Quantification of total mercury (ng/mg protein) in astrocytes following 24 hour incubation with luM 
MeHg. Following incubation with mercury, cells were washed with PBS and media was replaced with 
mercury-free DMEM for the times indicated on the abscissa. Media was then aspirated and cells were collected 
in a commercial lysis buffer. 
An in vitro concentration of 1 uM MeHg was selected for all dosing experiments. 
This dose was chose in order to cause sufficient Hg accumulation in primary cultures of 
astrocytes without inducing cytotoxicity. A study in which primary cortical astrocytes were 
isolated using a similar method inhibited 45% of glutamine synthase activity with 1 OuM 
MeHg (Allen et al., 2001). Glutamate uptake in cerebellar astrocytes was inhibited by 50 uM 
MeHg (Syversen et al., 2003). In our experiments, under normal conditions, an 80% 
confluent astrocyte culture resulted in the detection of approximately 5 ng of Hg - about 1 
000 fold greater than the published limit of detection (5 pg) (Nippon Instrument, Osaka, 
Japan). 
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Mercury analysis 
Total mercury was measured using an oxygen combustion gold amalgamation 
mercury analyzer with a cold vapour atomic absorption spectrophotometer detector (Nippon 
Instruments, Osaka, Japan). 50uL of the 200uL sample were pipetted into a ceramic boat and 
treated as a liquid sample in accordance with the operations manual. All samples were tested 
in triplicate and accuracy was determined by measuring mercury in DOLT3 and DORM2 
certified reference standards from the Canadian National Research Council (Ottawa, 
Ontario, Canada) with recovery within 10% of the reported values. Experimental quantities 
were normalized based on certified reference values. 
Quantification of organic mercury 
Because the particular mercury analyzer used was limited to determining the total 
mercury in a sample, a series of organic mercury extractions were performed according to a 
standard protocol developed by Callum el al. (1981). In brief, the samples were 
homogenized and processed to release protein-bound mercury with NaOH and CUSO4 
followed by the addition of sulphuric acid. Then, organic mercury was extracted using two 
liquid-liquid extractions with equal volumes of toluene. 4 mL (80%) of the extracted 
mercury was collected in a separate tube and mixed with sodium thiosulphate, which was 
then collected and placed directly in the mercury analyzer for analysis. Organic mercury was 
compared to DOLT3 and DORM2 certified reference materials from the Canadian National 
Research Council (Ottawa, Canada) for accuracy. Experimental quantities were normalized 
based on certified reference values. 
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Statistical Analysis 
All statistical analyses were conducted using R statistical software (R Foundation for 
Statistical Computing, Vienna, Austria). Graphs were generated using Sigmaplot (Systat Inc. 
California, USA). Comparisons of treatment and mercury types were accomplished by 
analysis of variance (ANOVA) followed by pair-wise comparisons using Tukey's HSD test, 
and were adjusted by the Bonferroni Correction to control for inflated Type I error (false 
positives). All statistics are expressed as mean ± SE. Values were considered to be 
significantly different at p<0.05. 
Results 
Cell culture purity 
Astrocytes and neurons were isolated as described above were analyzed for purity 
using FACS. Figure 3 shows the forward (FSC) and side scatter (SSC) plot for cultured 
astrocytes. Astrocytes were selected based on their size and granularity. The location of the 
major population in the neuroblastoma cell line (see Figure 3A) differed from the location of 
the astrocyte colony (Figure 3B). The astrocyte population has limited neuronal 
contamination as seen by the absence of events in the region where neurons appear. 
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/ 
Figure 3: Forward and side-scatters of: (A) the human neuroblastoma line SH-SY-5Y and (B) rat cerebellar 
astrocytes as determined by FACS. 
Protein Concentrations 
All of the samples analyzed for mercury and ROS were standardized for protein 
content to control for variable cell concentrations in treatment wells. Figure 4 shows the 
mean protein levels from the three treatment groups for the mercury samples collected. BSO 
protein levels were significantly lower than those of the control (1.58 ±0.107 vs. 1.13±0.067 
mg/mL, pO.OOl). Rotenone protein levels were not significantly different from control 
(1.58 ±0.107 vs. 1.30±0.085mg/mL). 
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Figure 4: Comparison of protein concentrations in rat astrocytes following 24 hour incubation with luM 
MeHg in the control, BSO, Rotenone treatment groups. 5 uL samples of the 200uL cell lysate were comparted 
to 5uL bovine serum albument standards using the Bradford protein quantification assay. Numbers in 
parentheses represent the number of independent experiments done on that particular treatment group. 
*p<0.001 vs. control 
Determination of Oxidative Stress 
Since ROS are highly reactive, it is not possible to accurately obtain a quantitative 
standard curve. Accordingly, data are presented in Figure 5 in relative fluorescence units 
(RFU) as percent of control per mg protein. BSO produced a 21% increase in ROS content 
as compared to the control (control vs. BSO; 100±1.35 vs. 121±1.52 RFU/mg protein, 
p<0.001). Rotenone increased ROS levels significantly greater than the control (control vs. 
rotenone; 100%±1.35 vs. 207%±6.78 RFU/mg protein, p<0.001). 
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Figure 5: Evaluation of free radical production in astrocytes following 24 hour incubation of pro-oxidant 
treatment. Cultures were incubated with either rotenone or BSO for 24 hours. Culture medium was replaced 
with PBS containing 5 uM DCFH for 15 minutes. Cultures were then rinsed and lysed by sonication in ImL 
PBS and fluorescence was measured. Since a standard curve could not be generated, a value of each treatment 
in arbitrary units was compared to that of the control to yield a relative fluorescence. Numbers in parentheses 
represent the number of independent experiments done on that particular treatment group. *p<0.01 vs. control. 
**p<0.001 vs. control. 
Mercury Dosing 
Following a series of trial runs, it became apparent that washing the cells with PBS 
was not sufficient to completely rid the culture wells of extracellular mercury. We 
hypothesized that mercury was adsorbing to the sides of the culture well. To test for this, 
treated cells were washed and placed in mercury-free culture media. The amount of mercury 
present following incubation in mercury-free solution for different time periods is listed in 
Figure 2. There was a sharp decline in mercury content between the 0 minute and 15 minute 
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groups, suggesting the removal of contaminating extracellular mercury. Mercury levels after 
15 minutes declined at a much slower rate, indicating mercury loss by diffusion. 
The BSO group, although slightly elevated from the control (control vs. BSO = 
86.53±4.14ng/mg vs. 95.74±9.26ng/mg), did not significantly increase total mercury 
accumulation (see Figure 6). There were no differences in the accumulation rates for organic 
mercury between treatments. In contrast, rotenone increased the accumulation of total 
mercury (control vs. rotenone = 86.53±4.14ng/mg vs. 123.6±3.80ng/mg, p<0.001) but not 
organic mercury (control vs. rotenone = 88.55±3.48ng/mg vs. 103.15±3.82ng/mg). 
Percent demethylation was expressed as the proportion of total mercury that was in 
the inorganic form relative to the total concentration (see Figure 7a for a sample calculation). 
An increase in demethylation for the BSO group was observed as compared to the control 
(control vs. BSO = -1.86±5.57% vs. 6.11±5.62%) (Figure 7b).Percent demethylation was 
significantly higher in the rotenone group than control (control vs. rotenone = -1.86±5.57% 
vs. 16.27±2.68%, p<0.05). 
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Treatment Group 
Figure 6: Effect of pro-oxidant treatment on mercury concentrations in cultured astrocytes. Total and organic 
mercury concentrations were collected following 24 hour incubation with luM MeHg *p<0.001 vs. control. 
Numbers in parentheses represent the number of independent experiments done on that particular treatment 
group. 
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Figure 7: Effect of pro-oxidant treatment on mercury demethylation in cultured astrocytes. % demethylation 
was calculated according to the equation given (A).Total and organic mercury concentrations were collected 
following 24 hour incubation with 1 uM MeHg (B). Numbers in parentheses represent the number of 
independent experiments done on that particular treatment group. *p<0.05 vs. control 
Discussion 
The present study demonstrates that, under specific conditions, demethylation can 
occur in astrocytes in vitro. This is consistent with a study conducted by Yasutake and 
Hirayama (2001) who successfully showed increased demethylation in rat liver slices 
incubated in the presence of rotenone. 
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As mentioned above, protein levels were quantified as a means of standardizing for 
variability in cell numbers between treatment groups. A reported disadvantage of the 
Bradford assay is that it underestimates protein concentration in the presence of certain 
detergents (Bradford, 1976) due to the disruption of hydrophobic and Van der Waals 
interactions (Compton and Jones, 1985). Interestingly, the protein content from stimulated 
rabbit muscle cells were underestimated by the Bradford assay in the presence of protein 
oxidation (Klebl et al., 1998). Accordingly, the decrease in observed protein content in the 
BSO group may be related to increased protein oxidation. The specificity of rotenone could 
have mitigated interference with the Bradford assay due to its localization in the 
mitochondria. There was concern that the significantly lower protein concentration in the 
BSO group would lead to an artificial skew in ROS detection and mercury concentration. 
The BSO group showed a small but significant increase in ROS production. While this is not 
surprising as BSO is a classic pro-oxidant, it may have been artificially increased by 
underestimation of protein content. It is therefore plausible that the detected ROS levels may 
be slightly elevated from the actual levels. Similarly, decreased protein levels could have 
significantly affected mercury accumulation levels in the BSO group. However, our results 
indicate no significant difference from the control. That said, the slight increase in the BSO 
group could be the result of increased reactive oxygen levels. 
This theory is consistent with the results for the rotenone group which revealed a 
marked increase in mercury accumulation to accompany the high oxidative stress. There 
may be a correlation between oxidative stress and mercury accumulation. If this is the case, 
the accumulation of mercury may be exacerbated by the finding that mercury induces 
oxidative stress (Syversen et al., 2006; Aramaki et al., 2004) through inactivation of the 
ubiquinone cytochrome c reductase complex in mitochondria (Yee and Choi, 1996). 
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The rotenone group revealed a marked increase in mercury accumulation to 
accompany the high oxidative stress suggesting a correlation between oxidative stress and 
mercury accumulation. If this is the case, the accumulation of mercury may be exacerbated 
by the finding that mercury induces oxidative stress through inactivation of the ubiquitine 
cytochrome c reductase complex in mitochondria (Yee and Choi, 1996). 
The reason for increased accumulation is not known; however, our results revealed a 
significant increase in total mercury in rotenone vs. control. Organic mercury levels were not 
statistically different from one another. This would imply that mercury accumulation 
depends on the degree of demethylation. It is possible that the conversion from organic 
mercury to inorganic mercury offsets the chemical equilibrium, thus causing an influx of 
mercury into the cells to re-establish the equilibrium of MeHg. Moreover, a number of 
previous studies have shown that iHg, at the site of injury, is the more potent species for 
toxicity (Aschner et al., 2007; Basu et al., 2005). These findings raise increasing concern 
about demethylation in the brain, as it appears to be a combination of both increased 
mercury accumulation and increased potency, thus substantiating the need to further 
understand and limit demethylation in the brain and other target organs. 
In the control and BSO groups, a high degree of variability was seen with levels of 
demethylation while the rotenone group was relatively more consistent. It is conceivable that 
the variability could be due to the unpredictability of ROS production. Cultured rat 
astrocytes have been shown to express the majority of the cell's GSH content in the 
cytoplasm (27 ± 3 nmol/mg protein in cytoplasm vs. 0.49 ± 0.07 nmol/mg in mitochondria) 
(Muyderman et al., 2004). In contrast, rotenone, which showed a relatively low variability, is 
a specific mitochondrial pro-oxidant (Sherer et al., 2003). If correct, this hypothesis provides 
support the idea that demethylation occurrs in the mitochondria. 
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We have successfully established a novel in vitro system in which a greater degree of 
oxidative stress increased demethylation as well as the accumulation of total mercury in 
cultured cerebellar astrocytes. A necessary next step will be to evaluate whether or not 
demethylation and accumulation can be reversed in the absence of oxidative stress. Beyrouty 
and Chan (2006) noted that the co-consumption of vitamin E and selenium - two nutrients 
which are known antioxidants - decreased toxicity of mercury but had no apparent effect on 
accumulation. The difficulty with using antioxidants in a primary cell culture is that many 
antioxidants have been problematic due to poor water solubility while water soluble 
chemicals do not cross into cells. We are currently investigating enzymes conjugated to 
lipophilic reagents to aid in delivery to cells. 
The observed effects in the rotenone group would suggest that demethylation is 
occurring in or around the mitochondria. An in vitro attempt has been made to culture 
purified mitochondria in a demethylation system (Aramaki et al., 2004; data not published); 
however, this study has yet to be published in a peer reviewed journal. Perhaps an easier 
method of analysis would be to determine the location of mercury using autometallographic 
staining on a transmission electron microscope similar to the studies performed in vivo by 
Charleston et al. (1995) and Pamphlett and Waley (1996). As mentioned, astrocytes take up 
MeHg in greater quantities than do neurons. Interestingly, astrocyte mitochondria have been 
found to be less tightly coupled to oxidative phosphorylation than those of neurons, 
indicating a greater degree of oxidative stress in astrocyte (Almeida and Medina, 1997). 
With the amout of global mercury on the rise (Slemr and Langer, 1992), decreasing 
the potency of mercury neurotoxicity is becoming more important. The major concern is that 
source mercury pollution can disperse throughout the world by evaporation and deposition. 
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The complete characterization of demethylation in the brain by oxidative stress may prevent 
increased incidence of mercury toxicity in light of increasing global concentrations. 
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5 Summary 
Mercury, a naturally occurring pollutant in the environment, exists in three different 
forms. These three forms have very different toxicological profiles not only because of their 
ability to enter and distribute throughout biological organisms, but also because of their 
specific effects at their respective sites of toxicity. A review of the available literature 
suggests that iHg and MeHg elicit toxicity through different mechanisms. This would 
explain why the toxicity endpoints for the two species are markedly different at certain sites. 
Specifically, iHg appears to preferentially target astrocytes while MeHg targets neurons. 
Since iHg does not penetrate the blood brain barrier, the presence of iHg in the brain 
following orally administered MeHg can only be explained by demethylation in situ. 
Findings such as these necessitate the characterization of demethylation in the brain. 
Accordingly, an in vitro system was developed which shows demethylation experimentally 
within 24 hours of exposure to MeHg. The pro-oxidants rotenone and BSO induced 
oxidative stress; however, only the rotenone group was able to induce demethylation in 
significant quantities (p<0.05 vs. control). The results from this study show that 
demethylation occurs in the brain and is driven by oxidative stress. Further understanding of 
this reaction may aid in decreasing toxicity in the future. 
6 Future Directions 
In order to complete the ultimate task of characterizing and subsequently controlling 
demethylation in the brain, the following issues must be addressed. Firstly, identifying the 
specific location of demethylation on an ultrastructural level is should be conducted so that a 
specific targeting system can be produced. Co-incubation of MeHg with rotenone, as 
outlined in section 4, indicates that demethylation may occur in mitochondria. Accordingly, 
autometallographic analysis of mercury under a transmission electron microscope, as 
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outlined by Charleston et al. (1995), should provide insight into the distribution of mercury 
in the brain under physiological conditions and under oxidative stress. Similarly, a chemical 
map on the same scale may be accomplished with x-ray absorption spectroscopy using a 
high powered synchrotron (7 GeV). Such a map would not only provide detail of mercury 
within the ultrastructure, but it would also indicate which species of mercury predominates 
by region. 
The second aspect would need to confirm that demethylation is caused by oxidative 
stress rather than a side reaction involving rotenone. Ideally, to confirm that rotenone caused 
demethylation via oxidative stress, a system with low ROS should be established. An in 
vitro system containing rotenone in the presence of poly ethylene glycol (PEG) conjugated 
superoxide dismutase and catalase could confirm our conclusions. 
Finally, the issue of why demethylation occurs in astrocytes but not appreciably in 
neurons should be addressed. As mentioned above, we believe that astrocytes have more 
mitochondria because they undergo division. Furthermore, astrocyte mitochondria have been 
shown to be coupled less tightly than those of neurons (Almeida & Medina, 1997) 
suggesting greater ROS production. Quantification of mitochondria in both cell types may 
aid in solving this quandary. 
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Appendix A: Animal Ethics Protocol 
UflBC UNIVERSITY OF NORTHERN BRITISH COLUMBIA 
ANIMAL USE PROTOCOL FOR LABORATORY ANIMALS 
IN 
RESEARCH OR TEACHING 
Office Use 
Protocol No. 
Category of Invasiveness 
Start Date 
End Date 
1. Administrative Information 
a) Name and title of principal investigator 
Laurie Chan, BC Leadership Chair, Professor 
b) Address for correspondence (include phone, fax and email) 
Dr. Laurie Chan, UNBC, Community Health Program, 3333 University Way, 
Prince George, British Columbia V2N 4Z9, Canada, Phone: 960-5237, Fax: 
960-5744 Email: lchan@unbc.ca 
c) Title of project/number and title of course 
Toxic and biochemical effects of mercury compounds on primary rat neurons and 
astrocytes 
d) Expected date of: commencement Sept 2006 conclusion Sept 
2007 
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e) Indicate what year this represents for a multi-year project: 1 
f) Type of project 
XD Research D Teaching 
g) XD New • Renewal of protocol no. 
For renewed protocols, please provide a copy of the original ACUC approved 
application 
and fill in sections 1 a) to 1 m) only. 
h) If renewal, 
• There have been no changes • There will be changes 
Provide justification for any proposed additions or changes. 
i) If renewal, list the number and species of animals used in this project over the 
last year. 
Indicate whether the numbers deviated from those targeted in the initial proposal. 
Describe any morbidity or mortality experiences for target and non-target 
species. 
N/A 
j) Location: 
Where will the study take place? (Name the closest town and the name of the 
laboratory) 
Animal facility in the Northern Medical Building. 
k) Permits 
Permits applied for Permits obtained (Y / N) Permit Number 
* Please provide photocopies of both sides of relevant licenses. 
1) Emergency Contact: 
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Name: Eric Bayrd 
Work Phone Number: 250-960-
5260 
Home Phone Number: 250-562-
8417 
ii) If this research / teaching / testing protocol has been approved by the Animal 
Care and Use 
Committee of an agency / institution other than UNBC, please submit a filled-
out and signed UNBC Animal Use Protocol form describing UNBC's 
involvement in the animal research/teaching/testing. In addition, please attach a 
copy of the other Agency's / Institution's authorized Animal Care and Use 
Protocol. 
P This protocol is not governed by UNBC's ACUC approval and is therefore 
provided for 
information only. 
• A copy of the authorized research protocol is attached. 
Name of the agency / institution whose ACUC authorized this research 
proposal: 
Declaration 
All animals used in this research project will be cared for in accordance with the 
policies and guidelines 
of the Canadian Council on Animal Care (http://www.ccac.ca) and the requirements 
of the relevant 
international, federal, provincial/territorial and municipal legislation. 
Signature, Principal Investigator / Course Director Date 
2. Source of Funding 
a) Funding agency(ies) or commercial sponsor: 
b) X Grant approved, agency file number: NSERC Discovery grant, account 
#21204 
c) • Grant under review 
3. Description of Use 
(If you need more information, please refer to CCAC's website at www.ccac.ca) 
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a) Purpose of Animal Use (PAU): 
Circle the number (1-6) below that best describes the purpose of animal use. 
1. Studies of a fundamental nature in sciences relating to essential structure or 
function (e.g. 
biology, psychology, biochemistry, pharmacology, physiology, etc.) 
( l) Studies for medical purposes, including veterinary medicine, that relate to 
human or animal 
disease or disorders. 
3. Studies for regulatory testing of products for the protection of humans, 
animals, or the environment. 
4. Studies for the development of products or appliances for human or veterinary 
medicine. 
5. Education and training of individuals in post-secondary institutions or 
facilities. 
6. Other: 
b) Lay Summary: 
Describe in terms understandable to the non-scientist how the proposed use of 
animals will contribute to the advancement of science, or to outcomes that can 
reasonably be expected to benefit humans, animals or the environment. 
Many neurotoxic environmental contaminants accumulate in foods such as fish 
and marine mammals. These foods are also nutritionally rich in vitamins and other 
micronutrients. However, pregnant women who consume these foods are exposed to 
contaminants, like mercury, which can affect brain development of their unborn 
babies. The objective of this study is to better understand how this toxic damage 
occurs and how antioxidants may protect the developing brain cells. 
We will isolate cells from the brain tissue of new-born rats. The cells will be 
grown in a culture-dish in the presence of mercury compounds. This cell culture 
technique is a widely accepted approach to understand how neurotoxic compounds 
can alter brain-cell development and function. We will then detect biochemical 
changes and signs of toxicity following exposure. Some chemical forms of mercury 
are less toxic to cells and so we will detect changes in mercury chemistry. We 
believe that some antioxidants, some of which are found in marine diets (i.e. vitamin 
E and selenium), are protective and may change mercury chemistry into a less toxic 
form. 
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c) Why is it necessary to use live animals, and what considerations has been given 
to the use of 
alternative methods which do not involve the use of animals? 
Before attempting this experiment on rats, we will be using commercially available 
brain "cell-lines" to optimize the experimental procedures. While the using 
commercial cell-lines do not require live animals, they are not considered a good 
model to understand brain development. Additionally, our technique does not 
require that animals be exposed to mercury compounds while alive. Using the cells 
harvested from euthanized rats eliminates the pain and suffering resulting from 
mercury exposure. 
d) Provide rationale for the choice of species. 
We have chosen the rat as it is generally accepted within the scientific community to 
serve as an model for this particular type of study (neurotoxicological bioassays). 
e) Animals to be used: 
Animal 
Sprague-
Dawley Rat 
Location 
NMB animal 
facility 
Number of 
animals required 
at a time 
2 formating, 14-
16 pups (average 
number of pups 
per fertilization) 
Annual total 
15 pups/2 weeks 
= 390/year+18 
adults/year for 
mating = 408 
Housing 
2 females per 
female cage. 1 
male per male 
cage 
* Provide justification for numbers of animals to be used. 
f) Agents to be administered: 
Indicate all agents to be administered in the research protocol for each species. 
None 
Species 
Sprague-
Dawley Rat 
Sprague-
Dawley Rat 
Agent 
Carbon 
dioxide gas 
Carbon 
dioxide gas 
Purpose 
Euthanize 
adult rats 
Anaesthetize 
neonatal pups 
Route 
Inhalation 
Inhalation 
Dosage 
100% 
100% 
Frequency 
Once 
Once 
g) Samples to be taken: 
Indicate all samples to be taken for each species. None 
Species Type of 
sample 
Site Amount Procedure Frequency 
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h) Details of procedures to be performed on animals: 
Descriptions must be sufficiently detailed to permit assessment of compliance 
with CCAC guidelines. Use terminology understandable to ACUC members 
with widely different backgrounds (including non-scientists). Indicate which 
members of the team will be carrying out which procedures. For killed 
specimens, describe the method to be used to destroy the animal. For complex 
projects with many procedures or those with routine procedures, it is easier to 
develop standard operating procedures (SOPs) in consultation with the ACUC. 
These can be attached to the application and referred to from this section. 
i. Describe all procedures and manipulations performed on live animals for 
each species. If multiple procedures are to be performed, flow diagrams 
may be useful. 
Mating 
Male and female adult Sprague-Dawley rats will be acclimatize for three weeks in 12 h 
light: 12 h dark cycle (12 L cycle starts at 7 am). Females will be introduced into the 
male's cage. Signs of mating (vaginal plug, swollen vagana) will be used as indicators of 
mating. 
Neonatal Period 
After birth, the offspring will be sacrificed 8 days after birth by decapitation using a 
guillotine by a trained researcher. According to the Canadian Council on Animal Care, 
this method of euthanasia is a virtually painless way to sacrifice animals without 
chemically contaminating tissues with anaesthesia. C02 gas mixtures are not appropriate 
for use in neonatal rats, and barbiturates can alter brain cells and invalidate the study. 
Brain cells will be collected, processed and cultured for experiments. Although not 
suitable for euthanasia, C02 gas will be used as a sedative prior to decapitation. Pups 
will be placed in small enclosures for 5 minutes under constant C02 gas flow until 
adequately sedated at which point, they will be decapitated. 
ii. For studies involving chemical restraint, detail the type of restraint 
chosen, provide details of immobilization agent used for chemical 
restraint, and describe all manipulations and precautions taken to protect 
the animal and investigator. 
Not applicable. 
iii. Provide details of marking, including potential long-term effects. 
Since animals will be sacrificed prior to experimentation, there is no potential for 
long-term effects. 
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iv. Provide details of any surgical and medical procedures. Indicate where 
and under what conditions it will be performed, as well as by whom. 
Provide the name of the veterinarian where consultation is necessary. 
Not applicable 
v. Provide details for post-procedure monitoring animals: What is the 
frequency (specified times per day, duration (number of days) and type 
(specific parameters of post procedure monitoring) over which post 
procedure monitoring of the animals will be performed. If post procedure 
monitoring is not necessary / applicable, this should be stated and 
explained as necessary. Provide details on post procedure nutritional 
requirements. 
Not applicable 
o first 24 hours: 
o second 24 hours: 
o thereafter: 
vi. Housing: Provide detail on the housing of the animals. 
Females will be housed up to 4 per cage but minimum of 2 per cage (shoebox cages). 
Males will be kept one to a cage (shoebox cage) except when a female is placed in their cage 
for mating. Bottom of the cage will be covered with wood chips. Each cage will have 
sufficient feed and access to water as described by the CCAC guidelines. Cage will be 
cleaned frequently to minimize the buildup of ammonia. 
4. Pain and Distress 
(If you need more information, please refer to CCAC's website at www.ccac.ca) 
a) Is any pain and / or distress likely to be associated with the procedures or 
manipulations? 
According to the CCAC, decapitation causes the immediate loss of consciousness 
and is acceptable form of euthanasia without anesthesia. As such, animals are not 
likely to experience any pain. There may be mild distress when positioning the 
animals in the guillotine. 
b) If animals encounter unanticipated pain and / or distress, what criteria will be 
used to terminate the 
procedure / study and possibly euthanize the animal(s)? 
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• 
• 
X 
discomfort 
• 
tolerance 
B 
C 
D 
E 
If adult animals show any sign of distress, they will be euthanized by carbon dioxide 
asphyxiation. If rats less than 10 days old show signs of distress/pain, they will be 
euthanized by decapitation. 
c) Indicate the category of invasiveness which best describes the protocol: 
• A Methods used on most invertebrates or on live isolates 
Methods used which cause little or no discomfort or stress 
Methods which cause minor stress or pain of short duration 
Methods which cause moderate to severe distress or 
Procedures which cause severe pain near, at, or above the pain 
Threshold of un-anesthetized conscious animals. 
5. Methods of Euthanasia 
(If you need more information, please refer to CCAC's website at www.ccac.ca) 
Provide details of method of euthanasia: 
i. For species of interest, where necessary upon termination of the study; 
Adult animals, once beyond their ability to produce viable offspring, will be 
sacrificed using carbon dioxide asphyxiation. 
ii. For species of interest, where necessary due to unanticipated pain and/or 
distress; 
Adult rats that show any signs of pain or distress will be sacrificed using carbon 
dioxide asphyxiation. Newborn rat pups will be sacrificed by decapitation if they 
are in pain/distress since asphyxiation is not considered appropriate at that age 
(less than 14days). 
6. Disposition 
(For further information, please refer to CCAC's website at www.ccac.ca) 
Provide details of intended fate of the animals used in the study. 
Animals in the study will be euthanized in order to harvest cells from specific regions 
of the brain. The cells will then be isolated, cultured and used in biochemical 
experiments. Mating adults will remain active until they are no longer able to 
produce viable offspring. Carcasses will be disposed of by incineration. Since they 
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will not be treated with anything prior to death, the carcasses will pose no harm 
chemically. Solid tissues not containing mercury will be discarded in normal 
biohazard waste containers. Tissues with mercury will be disposed of in appropriate 
mercury containers containing bleach. 
Potential Hazards to Staff, Students and Visiting Researchers 
(For further information, please refer to CCAC's website at www.ccac.ca) 
List potential biohazards, chemical and any other hazards. 
o Biohazards - Rat tissues 
o Chemical - carbon dioxide 
o Physical - guillotine blades 
Please provide an emergency contact name and number: 
Name: Laurie Chan 
Position / Relationship: Professor/Principal Investigator 
Phone Number: 960-5237 
Qualifications and Experience 
(For further information, please refer to CCAC's website at www.ccac.ca) 
List names, positions and relevant training and experience of all individuals who will 
be working directly with the animals. 
For Health & Safety Education and Training courses available at UNBC, please refer 
to the following website: http://www.unbc.ca/safety/trainina programs.html 
Name of individual, course taken, course provider and date of course 
Aaron Shapiro, BSc 
- Rat Embryo Culture Training; "hands-on" training and experience from Jiu-Ni Liu, 
McGill University, 1st to 10th December 2005 
- Animal Training Course (rodents and pigeons), Guelph University, 2004 
Eric Bayrd, MSc. 
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- no animal training 
Laurie Chan, PhD 
- Small animal handling course at McGill several years ago. 
I hereby certify that the above individual(s) is (are) qualified to conduct the procedures 
described and that they have read and initialled this application in person. 
Signature of principal investigator 
*** Copies *** 
15 copies (i.e. signed original plus 14 copies), each containing all attachments, should be 
submitted to: 
The Animal Care and Use Committee, Office of Research, 
3333 University Way, Prince George, B.C. V2N 4Z9 
(Telephone: (250) 960-5815, Fax: (250) 960-5746) 
Email: koehlerj@unbc.ca 
REVIEWED AT ACUC MEETING OF: 
APPROVED (Authorization of Chair): 
DATE APPROVED: 
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Appendix B: Certificate of Analysis: DORM-3 
National Research 
Council Canada 
Conseil national 
de recherches Canada 
DORMS 
Fish Protein Certified Reference Material for Trace Metals 
The following table shows those elements for which certified 
values have been established for this reference material. Certified 
values are based on unweighted mean results from data 
generated at NRCC as well as results submitted by laboratories 
participating in an annual intercomparison. The expanded 
uncertainty (U«„) in the certified value is equal to U = kt/.where i/0 
is the combined standard uncertainty calculated according to the 
ISO Guide [1] and k is the coverage factor. The value of uc is 
calculated from the combined uncertainties of the various 
methods (t/char) as well as uncertainties associated with 
homogeneity (i/,„,„). It is intended that UCTM accounts for every 
aspect that reasonably contributes to the uncertainty of the 
measurand [2]. A coverage factor of 2 was applied for all 
elements. The table below lists certified values for DORM-3 
expressed on a dry mass basis. 
TRACE ELEMENTS (milligram/kilogram) 
Arsenic (d,g,h) 
Cadmium (d,g,i,p) 
Copper (d.i.p) 
Chromium (d,g,i) 
Iron (d,i) 
Lead (d.g.p) 
Mercury (c,d,p) 
Nickel (d,g,i,p) 
Tin (d,p) 
Zinc (d,i,p) 
6.88 
0.290 
15.5 
1.89 
347 
0.395 
0.409 
1.28 
0.066 
51.3 
+ 
+ 
+ 
+ 
+ 
+ 
± 
+ 
+ 
+ 
0.30 
0.020 
0.63 
0.17 
20 
0.050 
0.027 
0.24 
0.012 
3.1 
Coding 
The coding refers only to the instrumental method used for quantitation. 
c - Cold vapour atomic absorption 
spectrometry, 
d - Inductively coupled plasma mass 
spectrometry, 
g - Electrothermal vaporization atomic 
absorption spectrometry. 
h - Hydride generation atomic absorption, 
fluorescence or emission spectrometry. 
i - Inductively coupled plasma atomic 
emission spectrometry. 
p - Isotope dilution inductively coupled plasma 
mass spectromet 
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Appendix C: Certificate of Analysis: DOLT-2 
National Research 
Council Canada 
Conseil national 
de recherches Canada 
O H 
• IMMlllflllfl 
V M H W 
DOLT-3 
Dogfish Liver Certified Reference Material for Trace Metals 
The following table shows those elements for which certified values have been 
established for this dogfish (Squalus acanthias) liver reference material. 
Certified values are based on unweighted mean results from data submitted by 
laboratories participating in an annual intercomparison. The expanded uncertainty 
(U„„) in the certified value is equal to U = kuewhere uc is the combined standard 
uncertainty calculated according to the ISO Guide [1] and k is the coverage factor. 
The value of uc is determined from the combined uncertainties of the various meth-
ods (Uchar) as well as uncertainties associated with homogeneity (u„m). 
It is intended that Uc™ encompasses every aspect that reasonably contributes to 
the uncertainty of the measurand [2,3]. A coverage factor of 2 was applied for all 
elements. The table below lists certifed values for DOLT-3. 
TRACE ELEMENTS (milligram/kilogram) 
Arsenic (d,g,h) 
Cadmium (d,f,g,i,p) 
Copper (d.i.p) 
Iron (d,f,i) 
Lead (d,g,p) 
Mercury (d,c,p) 
Nickel (g,i,p) 
Selenium (g,h,j) 
Silver (f.g.i.p) 
Zinc (d,i,p) 
10.2 
19.4 
31.2 
1484 
0.319 
3.37 
2.72 
7.06 
1.20 
86.6 
± 
± 
+ 
± 
+ 
± 
+ 
± 
+ 
+ 
0.5 
0.6 
1.0 
57 
0.045 
0.14 
0.35 
0.48 
0.07 
2.4 
Coding 
The coding refers only to the instrumental 
method of analyte determination. 
c - Cold vapour atomic absorption 
spectrometry, 
d - Inductively coupled plasma mass 
spectrometry 
f - Flame atomic absorption 
spectrometry, 
g - Electrothermal vaporization atomic 
absorption spectrometry (ETAAS). 
h - Hydride generation atomic absorption 
spectrometry, 
i - Inductively coupled plasma atomic 
emission spectrometry, 
j - Hydride generation atomic fluorescence 
spectrometry, 
p - Isotope dilution inductively coupled plasma 
mass spectrometry. 
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Appendix D: SH-SY-5Y Neuroblastoma Product Description 
Cell Biology 
ATCC® Number: 
Designations: 
BipsafetY Mwel: 
Medium & 
Serum: 
Organism: 
Order this item 1 
CRL-2266™ I 1 
SH-SY5Y 
1 
See Propaaation 
Homo sapiens (human) 
Price: 
Depositors: 
Shipped: 
Growth 
Properties: 
Morphology: 
$244 .00 
JL Biedler 
frozen 
mixed, adherent and suspension 
epithelial 
asm 
Source: Organ: brain 
Disease: neuroblastoma 
Derived from metastatic site: bone marrow 
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits 
may be required for the transfer of this ATCC material. Anyone purchasing ATCC 
material is ultimately responsible for obtaining the permits. Please click here for 
information regarding the specific requirements for shipment to your location. 
Related Cell Culture Products 
Restrictions: 
Isolation: 
Applications: 
Antigen 
Expression: 
DNA Profile 
(STR): 
Cytogenetic 
NOTE: SH-SY5Y was deposited at the ATCC by June L. Biedler, Memorial Sloan-
Kettering Cancer Center. SH-SY5Y is distributed for academic research purposes 
only. Memorial Sloan-Kettering releases the line subject to the following: 1.) SH-
SY5Y or its products must not be distributed to third parties. Commercial interests 
are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any 
proposed commercial use of SH-SY5Y including any use by a for-profit entity must 
first be negotiated with Director, Office of Industrial Affairs, Memorial Sloan-Kettering 
Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX 
(212) 717-3439. 
Isolation date: 1970 
(SH-SY5Y is a thrice cloned (SK-N-SH -> SH-SY -> SH-SY5 -> SH-SY5Y) subline of 
the neuroblastoma cell line SK-N-SH (see ATCC HTB-11) which was established in 
1970 from a metastatic bone tumor.) [23032] 
transfection host (Roche FuGENE® Transfection Reagents 
technology from amaxa) 
Blood Type A; Rh+ 
Amelogenin: X 
CSF1PO: 11 
D13S317:11 
D16S539: 8,13 
D5S818:12 
D7S820: 7,10 
THOl: 7,10 
TPOX: 8,11 
vWA: 14,18 
modal number = 47; the cells possess a unique marker comprised of a chromosome 
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Analysis: 
Age: 
Gender: 
Comments: 
Propagation: 
Subculturing: 
1 with a complex insertion of an additional copy of a lq segment into the long arm, 
resulting in trisomy of lq 
4 years 
female 
SH-SY5Y cells have a reported saturation density greater than 1 X 10(6) cells/sq cm. 
They are reported to exhibit moderate levels of dopamine beta hydroxylase activity 
[PubMed ID: 29704], 
ATCC complete growth medium: The base medium for this cell line is a 1:1 
mixture of ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-
2003, and F12 Medium. To make the complete growth medium, add the following 
components to the base medium: fetal bovine serum to a final concentration of 10%. 
Temperature: 37.0C 
Atmosphere: air, 95%; carbon dioxide (C02), 5% 
Protocol: These cells grow as a mixture of floating and adherent cells. The cells grow 
as clusters of neuroblastic cells with multiple, short, fine cell processes (neurites). 
Cells will aggregate, form clumps and float. 
Remove the medium with the floating cells, and recover the cells by centrifugation. 
Rinse the adherent cells with fresh 0.25% trypsin, 0.53 mM EDTA solution, add an 
additional 1 to 2 ml of trypsin solution, and let the culture sit at room temperature 
(or at 37C) until the cells detach. Add fresh medium, aspirate, combine with the 
floating cells recovered above and dispense into new flasks. 
Subcultivation ratio: A subcultivation ratio of 1:20 to 1:50 is recommended 
Preservation: 
Doubling Time: 
Related Products: 
References: 
Medium renewal: Every 4 to 7 days 
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO 
Storage temperature: liquid nitrogen vapor phase 
48 hrs 
recommended serum: ATCC 30-2020 
parental cell line: ATCC HTB-11 
22554: Ross RA , et al. Coordinate morphological and biochemical interconversion of 
human neuroblastoma cells. J. Natl. Cancer Inst. 71: 741-749, 1983. PubMed: 
6137586 
23032: Biedler JL , et al. Multiple neurotransmitter synthesis by human 
neuroblastoma cell lines and clones. Cancer Res. 38: 3751-3757, 1978. PubMed: 
29704 
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